Segmented peptide nanofibers for enhancing neural bioactivity
Segmented peptide nanofibers with controlled nucleation-growth assembly enhance neural bioactivity by replicating tissue inhomogeneity, addressing the challenge of synthetic materials in regenerative medicine.
Patent Information
- Application Number
- PCT/US2026/027617
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Synthetic materials that interface with biological tissues struggle to replicate the inhomogeneous nano- and micro-scale molecular composition of living tissue, making it difficult to enhance tissue healing and growth in regenerative medicine.
Development of peptide amphiphiles that self-assemble into segmented nanofibers with chemically diverse domains, utilizing a controlled nucleation-growth mechanism to create asymmetric fibers that enhance neural bioactivity by associating directly with neurons.
The segmented nanofibers significantly enhance neural growth by electrostatically anchoring to cell membranes and binding to extracellular proteins, providing mechanical support and biochemical signals.
Smart Images

Figure US2026027617_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket NWEST-45005.601
[0002] SEGMENTED PEPTIDE NANOFIBERS FOR ENHANCING NEURAL BIOACTIVITY STATEMENT REGARDING RELATED APPLICATIONS
[0003] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 803,070, filed May 9, 2025, the entire contents of which are incorporated herein by reference for all purposes.
[0004] SEQUENCE LISTING
[0005] The text of the computer readable sequence listing filed herewith, titled “NWEST-45005-601_SQL.xml”, created May 8, 2026, having a file size of 15,742 bytes, is hereby incorporated by reference in its entirety.
[0006] FIELD
[0007] Provided herein are peptide amphiphiles, segmented peptide amphiphile nanofibers and methods of use thereof. In particular aspects, provided herein are peptide amphiphiles capable of nucleation-growth type self-assembly, segmented peptide amphiphile nanofibers comprising a mixture of positively charged and negatively charged segmented peptide amphiphiles, and uses of the same for cell culture.
[0008] BACKGROUND
[0009] The inhomogeneous nano- and micro-scale molecular composition of living tissue is fundamental to its function. Proteins and lipids cluster non-uniformly on the cell membrane, biomolecular signals for cell growth and development are spatially organized within tissues, and extracellular matrix components are intentionally aligned to guide cell-matrix interactions.
[0010] Synthetic materials that interface with, influence, or reinforce natural biological phenomena should possess these same inhomogeneous structural and chemical properties to maximize compatibility. The field of regenerative medicine aims to use bioinspired materials to provide both mechanical support and biochemical signals to cells to enhance tissue healing and growth. Synthetic mimics of the extracellular matrix have been built using polymers, peptides, and supramolecular nanostructures - functionalized with bioactive signals, and featuring tunable, stimuli-responsive mechanical properties. However, soft nanomaterials designed to integrateAttorney Docket NWEST-45005.601
[0011] with and affect biological tissues by mirroring their spatial inhomogeneity remain difficult to synthesize. Synthetic materials with increased complexity by incorporating nano- or microscale inhomogeneity are needed to further amplify the body’s own capacity for healing, advancing the impact of regenerative medicine.
[0012] SUMMARY
[0013] Synthetic one-dimensional nanofibers with nano- or micro-sized domains of distinct molecular composition are ideal inhomogeneous biomimetic nanoparticles to interface with cells for regenerative medicine. Herein, peptide amphiphiles (PAs) were developed that self-assemble through a controlled nucleation-growth mechanism to generate segmented and asymmetric nanofibers with precise dimensions. Using a multi-step living supramolecular polymerization process, nanofibers were synthesized with chemically diverse PA domains along their lengths. By including a small positively charged peptide amphiphile segment surrounded by adjacent negatively charged peptide amphiphile segments, the segmented nanofibers herein are demonstrated to directly associate with neurons and substantially enhance their growth. Living polymerization of the fibers occurs at different rates from the two ends, breaking their symmetry. By systematically varying the molecular structure of the PAs, general rules that enable the controlled nucleation-growth of PA fibers were developed, and it was discovered that PEG surprisingly plays an integral role in the living polymerization of the peptide amphiphiles herein.
[0014] In some aspects, provided herein is a peptide amphiphile comprising a hydrophobic tail, a - sheet forming peptide segment, a charged peptide segment comprising one or more repeating XGG units, and a PEG domain, wherein X is a positively charged amino acid or a negatively charged amino acid. In some embodiments, the hydrophobic tail comprises an 8-24 carbon alkyl chain (Cs-24). In some embodiments, the 0-sheet forming peptide segment comprises 2 to 6 amino acids and has a total propensity for forming 0-sheet conformations of at least 4. In some embodiments, the 0-sheet-forming segment has a total propensity for forming beta-sheet conformations of 4 or more and produces nanofibers (e.g. “ribbons”) having a flat morphology or produces twisted nanofibers having a consistent pitch length. For example, in some embodiments the 0-sheet forming peptide segment comprises V2A2 (SEQ ID NO: 1).
[0015] In some embodiments, the PEG domain comprises a PEG containing 10 to 30 repeating ethylene glycol subunits.Attorney Docket NWEST-45005.601
[0016] In some embodiments, the charged peptide segment comprises 2 to 10 repeating XGG units (e.g. 2, 3, 4, 5, 6, 7, 8, 9, or 10 repeating XGG units). For example, in some embodiments the charged peptide segment comprises 2 to 4 repeating XGG units.
[0017] In some embodiments, the X is arginine (R). In some embodiments, the peptide segment comprises 2 to 10 repeating RGG units (e.g. 2, 3, 4, 5, 6, 7, 8, 9, or 10 repeating RGG units). In some embodiments, the peptide segment comprises 2 to 4 repeating RGG units. In some embodiments, the peptide segment comprises (RGG)? (SEQ ID NO: 2).
[0018] In some embodiments, the X is glutamic acid (E). In some embodiments, the peptide segment comprises 2 to 10 repeating EGG units (e.g. 2, 3, 4, 5, 6, 7, 8, 9, or 10 repeating EGG units). In some embodiments, the peptide segment comprises 2 to 4 repeating EGG units. In some embodiments, the charged peptide segment comprises (EGG)? (SEQ ID NO: 3).
[0019] In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1). a charged peptide segment comprising one or more repeating RGG units, and a PEG domain. In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a charged peptide segment comprising 2 to 10 repeating RGG units, and a PEG domain. In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24). a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1) a charged peptide segment comprising one or more repeating RGG units, and a PEG domain comprising 10 to 30 ethylene glycol subunits. In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a charged peptide segment comprising 2 to 10 repeating RGG units, and a PEG domain comprising 10 to 30 repeating ethylene glycol subunits.
[0020] In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1) a charged peptide segment comprising one or more repeating EGG units, and a PEG domain. In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a p-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a charged peptide segment comprising 2 to 10 repeating EGG units, and a PEG domain.Attorney Docket NWEST-45005.601
[0021] In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a charged peptide segment comprising one or more repeating EGG units, and a PEG domain comprising 10 to 30 ethylene glycol subunits. In some embodiments, the peptide amphiphile comprises a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a charged peptide segment comprising 2 to 10 repeating EGG units, and a PEG domain comprising 10 to 30 repeating ethylene glycol subunits.
[0022] In some aspects, provided herein is a segmented nanofiber comprising a positively charged peptide amphiphile segment flanked on one end by a first negatively charged peptide amphiphile segment and flanked on the other end by a second negatively charged peptide amphiphile segment. In some embodiments, the positively charged peptide amphiphile segment comprises one or more positively charged peptide amphiphiles, each positively charged peptide amphiphile comprising a hydrophobic tail, a P-sheet forming peptide segment, a positively charged peptide segment comprising one or more repeating XGG units, wherein X is a positively charged amino acid, and a PEG domain. In some embodiments, the first negatively charged peptide amphiphile segment and the second negatively charged peptide amphiphile segment each comprise one or more negatively charged peptide amphiphiles, each negatively charged peptide amphiphile comprising a hydrophobic tail, a P-sheet forming peptide segment, a negatively charged peptide segment comprising one or more repeating XGG units, wherein X is a negatively charged amino acid, and a PEG domain.
[0023] In some embodiments, the hydrophobic tail of the one or more positively charged peptide amphiphiles and the one or more negatively charged peptide amphiphiles comprises an 8-24 carbon alkyl chain (C8-24). In some embodiments, the P-sheet forming peptide segment of the one or more positively charged peptide amphiphiles and the one or more negatively charged peptide amphiphiles comprises 2 to 6 amino acids and has a total propensity for forming p-sheets of at least 4. In some embodiments, the P-sheet-forming segment of the one or more positively charged peptide amphiphiles and of the one or more negatively charged peptide amphiphiles has a total propensity for forming beta-sheet conformations of 4 or more and produces nanofibers having a flat morphology, or produces twisted nanofibers having a consistent pitch length. InAttorney Docket NWEST-45005.601
[0024] some embodiments, the 0-sheet forming peptide segment of the one or more positively charged peptide amphiphiles and of the one or more negatively charged peptide amphiphiles comprises V2A2 (SEQ ID NO: 1). In some embodiments, the PEG domain of the one or more positively charged peptide amphiphiles and the one or more negatively charged peptide amphiphiles comprises a PEG containing 10-30 repeating ethylene glycol subunits. In some embodiments, the positively charged peptide segment and the negatively charged peptide segment comprise 2 to 10 repeating XGG units (e.g. 2, 3, 4, 5, 6, 7, 8, 9, or 10 repeating XGG units). In some embodiments, the positively charged peptide segment and the negatively charged peptide segment comprise 2 to 4 repeating XGG units. In some embodiments, the positively charged amino acid is arginine (R). In some embodiments, the positively charged peptide segment comprises 2 to 10 repeating RGG (e.g. 2, 3, 4, 5, 6, 7, 8, 9, or 10 repeating RGG units), units. In some embodiments, the positively charged peptide segment comprises 2 to 4 repeating RGG units. In some embodiments, the positively charged peptide segment comprises (RGG)s (SEQ ID NO: 2). In some embodiments, the negatively charged amino acid is glutamic acid (E). In some embodiments, the negatively charged peptide segment comprises 2 to 10 repeating EGG units (e.g. 2, 3, 4, 5, 6, 7, 8, 9, or 10 repeating EGG units). In some embodiments, the negatively charged peptide segment comprises 2 to 4 repeating EGG units. In some embodiments, the negatively charged peptide segment comprises (EGG)3 (SEQ ID NO: 3).
[0025] In some embodiments, the positively charged peptide amphiphile segment comprises a plurality of (e.g. 2 or more) positively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a -sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a positively charged peptide segment comprising one or more repeating RGG units, and a PEG domain. In some embodiments, the positively charged peptide amphiphile segment comprises a plurality of (e.g. 2 or more) positively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a positively charged peptide segment comprising one or more repeating RGG units, and a PEG domain containing 10-30 repeating ethylene glycol subunits. In some embodiments, the positively charged peptide amphiphile segment comprises a plurality of (e.g. 2 or more) positively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a positively charged peptideAttorney Docket NWEST-45005.601
[0026] segment comprising 2 to 10 repeating RGG units, and a PEG domain. In some embodiments, the positively charged peptide amphiphile segment comprises a plurality of (e.g. 2 or more) positively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a positively charged peptide segment comprising 2 to 10 repeating RGG units, and a PEG domain containing 10-30 repeating ethylene glycol subunits. In some embodiments, the positively charged peptide amphiphile segment comprises at least 2, at least 10, at least 25, at least 50, at least 100, at least 250, at least 500, at least 1,000, at least 2,500. at least 5,000, at least 7,500, at least 10,000, at least 25,000, at least 50,000, at least 75,000, at least 100,000, at least 250,000, at least 500,000, at least 750,000, or about 1,000,000 positively charged peptide amphiphiles.
[0027] In some embodiments, the negatively charged peptide amphiphile segments each comprise a plurality of (e.g. 2 or more) negatively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a negatively charged peptide segment comprising one or more repeating EGG units, and a PEG domain. In some embodiments, the negatively charged peptide amphiphile segments each comprise a plurality of (e.g. 2 or more) negatively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24). a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a negatively charged peptide segment comprising one or more repeating EGG units, and a PEG domain containing 10-30 repeating ethylene glycol subunits. In some embodiments, the negatively charged peptide amphiphile segments each comprise a plurality of (e.g. 2 or more) negatively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24). a P-sheet forming peptide segment comprising V2A2 (SEQ ID NO: 1), a negatively charged peptide segment comprising one 2 to 10 repeating EGG units, and a PEG domain. In some embodiments, the negatively charged peptide amphiphile segments each comprise a plurality of (e.g. 2 or more) negatively charged peptide amphiphiles, each comprising a hydrophobic tail comprising an 8-24 carbon alkyl chain (Cs-24), a P-sheet forming peptide segment comprising V2A2, a negatively charged peptide segment comprising one 2 to 10 repeating EGG units, and a PEG domain containing 10-30 repeating ethylene glycol subunits. In some embodiments, at least one of the negatively charged peptide amphiphile segmentsAttorney Docket NWEST-45005.601
[0028] comprises at least 2, at least 10, at least 25, at least 50, at least 100, at least 250, at least 500, at least 1,000, at least 2,500, at least 5,000, at least 7,500, at least 10,000, at least 25,000, at least 50,000, at least 75,000, at least 100,000, at least 250,000, at least 500,000, at least 750,000, or about 1,000,000 negatively charged peptide amphiphiles. In some embodiments, the negatively charged peptide amphiphile segments have different lengths.
[0029] In some embodiments, the segmented nanofiber has a total length of 5 pm to 35 pm. In some embodiments, the segmented nanofiber has a molecular weight of 1.0 x 108g / mol to 2.25 x 109g / mol. In some embodiments, the segmented nanofiber has a molecular weight of 1.5 x 108g / mol to 2.25 x 109g / mol. The skilled artisan would appreciate that the molecular weight will depend on the length of the segmented nanofiber. In some embodiments, the positively charged peptide amphiphile segment comprises less than 30%, less than 20%, or less than 15% of the entire nanofiber by length. In some embodiments, the two negatively charged peptide amphiphile segments have asymmetric lengths. In some embodiments, the length of the first negatively charged peptide amphiphile segment is at least 50% greater than the length of the second negatively charged peptide amphiphile segment. In some embodiments, the length of the first negatively charged peptide amphiphile segment is at least double the length of the second negatively charged peptide amphiphile segment.
[0030] In some aspects, provided herein is a method comprising contacting a cell with a segmented nanofiber described herein. In some aspects, provided herein are cells cultured on a segmented nanofiber herein. In some embodiments, the cell is a neuron.
[0031] In some aspects, provided herein is a system comprising a cell and the segmented nanofiber herein, wherein the positively charged peptide amphiphile segment is electrostatically anchored to the cell membrane, and wherein the positively charged peptide amphiphile segments bind to extracellular proteins in proximity to the cell, hr some embodiments, the cell is a neuron. In some embodiments, electrostatic interactions between the positively charged peptide segment and the cell membrane anchors the nanofiber to the cell.
[0032] BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F show length-controlled self-seeded assembly of (RGG)s-PEG20. FIG. 1A. Molecular structure of (RGG)3-PEG20 (C16-VVAAGRGGRGGRGG (SEQ ID NO: 4)-PEG10-Attorney Docket NWEST-45005.601
[0033] PEG10). FIG. IB. Variable temperature fluorescence measurement of (RGG)3-PEG20 melting using as nile red as probe. FIG. 1C. SAXS profiles of (RGG)3-PEG20 below and above the melting temperature. FIG. ID. Plot of length vs. Tanneai for (RGG)3-PEG20. N > 100 for each sample, with 100 randomly chosen data points displayed. For Tassembiy = 78 °C, length was measured by AFM. For Tassembiy = 80, 82, 85 °C, length was measured by CLSM. FIG. IE.
[0034] Schematic of the self-seeding mechanism in which Tassembiy controls the length of the resultant nanofibers. Very short bath-sonicated (RGG)3-PEG20 nanoparticles are heated to Tassembiy, where all but a small proportion of particles are melted. These unmelted particles then act as seeds for the supramolecular polymerization upon cooling. FIG. IF. Representative CLSM images of length-controlled (RGG)3-PEG20 nanofibers, following assembly at the indicated Tassembiy-
[0035] FIGS. 2A-2H show asymmetric living polymerization of segmented peptide amphiphile nanofibers. FIG. 2A. CLSM images of Segmented (RGG)3-PEG20 nanofibers with asymmetric end lengths grown at different “melt / seed” ratios. Cy-3 labelled “melt” (green) was grown from previously generated Cy-5 labelled “seeds” (pink). Top row: 0.25 pM PA; bottom row: 10 pM. Scale bars = 5 pm. FIG. 2B. Total lengths of fibers versus the melt / seeds ratio. Lv = 0.52r + 0.07, where r = melt / seed. FIG. 2C. Lengths of the short and long ends and the total lengths of the sample with melt / seed = 11. L v. iong= 3.7 pm, Diong = LOL LA?, short = 1.2 pm, Dshort = 1.09. L ?, total = 5.8 pm, Dtotai = 1.01. FIG. 2D. Molecular representation of the -sheet direction and asymmetric ends. FIG. 2E. Relative lengths of the short and long ends of fibers seeded at different temperatures then cooled 30 s / °C. Melt / seeds = 11. Tseeding = 60 °C: Diong = 1.02, Dshort = 2.3; Tseeding = 62.5 °C: Diong = 1.00, Dshort = 1.13; Tseeding = 65 °C: Diong = LOO, Dshort = 1.05; Tseeding = 68 °C: Diong = 1.04, Dshort = LOL FIG. 2F. PAI fibers with five discrete segments, generated through multiple rounds of living supramolecular polymerization. Scale bar = 5 pm. FIG. 2G. Lengths of segments of five-segment fibers, labelled sequentially from A to E, where A is the end segment with the shortest length. LA?, A = 1.2 pm, DA = 1.1, LA?,B = 1.5 pm, DB = 1.06, L ?,C = 0.8 pm, De = 1.04, LA?,D = 4.3 pm, DD = 1.04, L ?,E = 3.5 pm, DE = 1.04, LA?, total = 11.3 pm, Dtotai = 1.01. For all length measurements (B, C, E, G): N > 100; measured from CLSM or AFM (for Tassembiy = 78 °C). FIG. 2H. Very long segmented fibrils. Scale bar = 10 pm. L ?, total = 34 pm, Dtotai = 1.04.Attorney Docket NWEST-45005.601
[0036] FIGS. 3A-3F show synthesis of segmented fibers with adjacent regions of opposite charge. FIG. 3A. Molecular structure of (EGG)3-PEG20 (C16-VVAAGEGGEGGEGG (SEQ ID NO: 5)-PEG10-PEG10). FIG. 3B. Cryogenic electron micrograph of (EGG)3-PEG20. Blue and red arrows indicate two different orientations of fibers. Scale bar = 100 nm. FIG. 3C. 2D class of (EGG)3-PEG20 showing 4.9 A spacing indicative of beta sheets. Scale bar = 5 nm. FIG. 3D. Segmented (EGG)3-PEG20. Magenta: 2.5 mol% (EGG)2-PEG20-Cy5, green: 2.5 mol% (EGG)2-PEG20-Cy3. Melt / seed = 11. Scale bar = 2 pm. FIG. 3E. Segmented fibers with a positively charged (RGG)3-PEG20 center (2.5 mol% (RGG)3-PEG20-Cy5. magenta), and negatively charged (EGG)3-PEG20 ends (2.5 mol% (EGG)2-PEG20-Cy3, green). Panel on right is higher concentration imaging conditions. Scale bar left panel = 2 pm; right panel = 10 pm. FIG. 3F. RGG and EGG SAXS / WAXS comparison.
[0037] FIGS. 4A-4G show neuron growth is enhanced by segmented fibers. FIG. 4A. Fiber architectures administered to mouse cortical neuron culture. FIG. 4B. Live / dead assay of mouse cortical neurons treated with 45 pM of each PA architecture at 48 hours. FIG. 4C. Mean neurite length over time following treatment with 45 pM PA. Error bars represent the SEM. Neurite length was measured in real-time using between 40-50 images across two wells per treatment per time point. FIG. 4D. Dot plot of neurite length at 48 hours for each PA architecture treatment. Each dot is a separate image. FIG. 4E. Immunostained mouse cortical neuron morphology at 48 hours for different PA treatments. DAPI: blue, Tujl: green, phalloidin: red, SMI: blue. Scale bar = 50 pm. FIG. 4F, FIG. 4G. Interaction of dye-labelled PA architectures E (F) and segmented E-R-E (G) with mouse cortical neurons. DAPI: blue, Tujl: cyan, Cy3-labelled negatively charged fiber: green, Cy5-labelled positively charged fiber: magenta. Scale bars = 10 pm.
[0038] FIGS. 5A-5F show impact of amino acid sequence in the beta sheet region on the living supramolecular polymerization of peptide amphiphiles. FIG. 5A. Molecular structures of the amino acid regions of VVAA (SEQ ID NO: 1) and AAVV (SEQ ID NO: 6). Both have a C16 N-terminus and PEG10-PEG10 C-terminus that are not shown. FIG. 5B. CLSM image of attempted length-controlled living supramolecular polymerization of AAVV (SEQ ID NO: 6). Scale bar = 10 pm. Fibers were labelled with 2.5 mol% AAVV(SEQ ID NO: 6)-Cy5 (magenta) or AAVV(SEQ ID NO: 6)-Cy3 (green). FIG. 5C. CLSM image of attempted living supramolecular polymerization of AAVV (SEQ ID NO: 6) (2.5 mol% Cy3-labelled, green) from VVAA(SEQ IDAttorney Docket NWEST-45005.601
[0039] NO: 1) (2.5 mol% Cy5-labelled, magenta) seed segments. Scale bar = 10 m. FIG. 5D.
[0040] Representative cryo-TEM micrographs. FIG. 5E. Nanofiber twist frequency measurements. F. SAXS and WAXS.
[0041] FIGS. 6A-6F show pegylated PAs stabilize fiber lengths and inhibit fiber-fiber interactions. FIG. 6A. Molecular structures of the charged and PEG regions of PAs. Variations from (RGG)3-PEG20 highlighted in orange. All have a C16-VVAAG (SEQ ID NO: 7) N-terminus. FIG. 6B. TEM micrographs of E-based PAs (with and without PEG), immediately following probe sonication and 24 hours later. FIG. 6C. Possible molecular mechanism for fiber end stabilization by PEG. FIG. 6D. TEM micrograph of (RGG)2R following probe sonication and also aging for 24 hours. FIG. 6E. Circular dichroism (CD) of R-based PAs with different charged and PEG regions. Molar ellipticity is on a per amino acid basis. FIG. 6F. SAXS and WAXS of PEG10, PEG20, PEG30, RGGR (SEQ ID NO: 8), RRR.
[0042] FIG. 7A. Transmission electron microscopy (TEM) of (RGG)3-PEG20 in IxPB, pH 7.4, 150 mM NaCl, following assembly at 99 °C. Scale bar on left is 250 nm, on right 1000 nm. FIG.
[0043] 7B. Confocal laser scanning microscopy (CLSM) image of (RGG)3-PEG20) coassembled with 2 mol% (RGG)3-PEG20-Cy3 in IxPB, pH 7.4, 150 mM NaCl, following assembly at 99 °C. Scale bar = 10 pm.
[0044] FIG. 8A. Variable temperature fluorescence measurement of nile red with (RGG)3-PEG20 during cooling. Sample was cooled at 1 °C / min in IxPB, pH 7.4, 150 mM NaCl.
[0045] Experiment was run in triplicate. FIG. 8B. Variable temperature polarized optical microscopy experiment on (RGG)3-PEG20, pre-assembled at 99 °C and 1 mM. Birefringence intensity was measured as temperature increased. Sample was heated at 1 °C / min in IxPB, pH 7.4, 150 mM NaCl.
[0046] FIG. 9. Atomic force microscopy images in air on mica of (RGG)3-PEG20 following assembly at 78 °C. LTV = 0.4 pm, D = 1.1.
[0047] FIG. 10. Shear viscosity of C16-VVAAGRGGRGGRGG (SEQ ID NO: 4)-PEG10-PEG10 fibrils following annealing at different temperatures at 1 mM. Different annealing temperatures correspond to different fibril lengths (see Fig. ID). PBS is buffer with no fibrils.Attorney Docket NWEST-45005.601
[0048] FIG. 11 shows (RGG)3-PEG20 with 2 mol% (RGG)3-PEG20-Cy3 in IxPB, pH 7.4, 150 mM NaCl, unassembled and bath sonicated for 5 minutes. Scale bars: left = 1pm, right = 250 nm
[0049] FIGS. 12A-12E show a reassembly study of (RGG)3-PEG20. FIG. 12A. (RGG)3-PEG20 assembled at 80°C. FIG. 12B. Sample from FIG. 12A following re-assembly at 78 °C. FIG. 12C. Sample from FIG. 12A following re-assembly at 80 °C. FIG. 12D. Sample from FIG. 12A following re-assembly at 82 °C. CLSM images, scale bar = 10 pm. FIG. 12E. Lengths of samples shown in panels A to D (green), and lengths of (RGG)3-PEG20 assembled independently from unassembled, bath sonicated material (black, as shown in Fig. 1).
[0050] FIG. 13 A. Derivative melting curves of (RGG)3-PEG20 fibers of different lengths.
[0051] Legend indicates lengths of fibers prior to melting. Different length fibers were generated using the self-seeded method. For length = 0.4 pm, Tassembly — 78 °C; length = 2.6 pm, Tassembly — 80 °C; length = 6.2 pm, Tassembiy= 82 °C; length = 20.3 pm, Tassembly = 85 °C; length = very long, Tassembly = 99 °C. FIG. 13B. Melting temperature (Tmeiting) of fibers pre-assembled at different temperatures. Points are the peaks of the curves in A.
[0052] FIGS. 14A-14D show dynamic molecular exchange and mixing of PA molecules between fibers over time. FIG. 14A. Experimental design illustrating the experimental, negative control, and positive control conditions, and some potential changes to the experimental condition over time. FIG. 14B. Fluorescence spectra of the three conditions 32 hours after mixing the separately assembled (RGG)3-PEG20-Cy3 (2 mol% Cy3 labelled, green) and (RGG)3-PEG20-Cy5 (2 mol% Cy5 labelled, magenta) fibers. FIG. 14C. Normalized RFU at 574 nm over time, showing the slight decrease in Cy3 emission in the experimental condition. FIG.
[0053] 14D. FRET efficiency over time of the experimental condition
[0054] FIGS. 15A-15C show dynamic molecular exchange and mixing of (RGG)3-PEG20 molecules between fibers over time. CLSM characterization six days following mixing of (RGG)3-PEG20-Cy3 (2 mol% Cy3 labelled, green) and (RGG)3-PEG20-Cy5 (2 mol% Cy5 labelled, magenta) in the experimental condition is shown in FIG. 15 A, and in the control condition is shown in FIG. 15B. Distinct Cy3 and Cy5 fibers are clearly visible in the experimental condition. Lengths of (RGG)3-PEG20-Cy3 (2 mol% Cy3 labelled, green) and (RGG)3-PEG20-Cy5 (2 mol% Cy5 labelled, magenta) fibers in the experimental condition sixAttorney Docket NWEST-45005.601
[0055] days after mixing the two pre-assembled populations are shown in FIG. 15C. For Cy3-labelled fibers: L,v= 5.8 pm, D = 1.05. For Cy5-labelled fibers: L<v = 2.7 pm, D = 1.02.
[0056] FIG. 16A-16D. Dynamic molecular exchange and mixing of PA molecules between (RGG)3-PEG20 fibers overtime. FIG. 16A. Observed FRET upon mixing separately assembled fibers and the set-up for measuring the FRET efficiency of 0.125 mol fraction mixture for use in a standard curve. FIG. 16B. Individual fluorescence spectra of the two partially mixed fibers and their linear combination. FIG. 16C. Emission spectra of prepared mixtures of partially mixed fibers, where A is the minor component in the mixture. Each spectrum is the result of the addition of two individually measured spectra to avoid additional dynamic mixing of the components that would occur if the solutions were mixed before measuring. FIG. 16D. Standard curve of FRET efficiency vs. mole fraction in mixed Cy3 and Cy5 fibers, where A is the minor component in each fiber.
[0057] FIG. 17. (RGG)3-PEG20 in IxPB, pH 7.4, 150 mM NaCl, unassembled and probe sonicated. Seeds used for manually seeded growth. Scale bar = 250 nm.
[0058] FIG. 18 A. Schematic of the seeded growth mechanism. (RGG)3-PEG20 seeds are added to melted (RGG)3-PEG20 just below the Tmeiting (65 °C), then cooled to room temperature. FIG.
[0059] 18B. Plot of length vs. melt / seeds ratio for (RGG)3-PEG20. N = 100 for each sample. Lengths were measured by CLSM. FIG. 18C. Representative CLSM images of length controlled (RGG)s-PEG20 nanofibers, following seeded growth using the molar melt / seed ratios shown (50x is defined as a melt / seed molar ratio of 50). Scale bar = 10 pm.
[0060] FIG. 19 Additional CLSM images of segmented (RGG)3-PEG20 nanofibers with asymmetric end lengths synthesized at different melt / seed values. Cy-3 labelled “melt” (green) was grown from previously generated Cy-5 labelled “seeds” (magenta). Scale bar = 10 pm.
[0061] FIG. 20A-20B show yields of three-segment (FIG. 20A) and five-segment (FIG. 20B) (RGG)3-PEG20 fibers. N = 118 for A and 223 for B.
[0062] FIG. 21. CLSM images of segmented (RGG)3-PEG20 nanofibers with asymmetric end lengths seeded at different temperatures (Tseeding). Cy-3 labelled “melt” (green) was grown from previously generated Cy-5 labelled “seeds” (magenta). Scale bar = 10 pm.
[0063] FIG. 22A. Schematic of the living supramolecular polymerization growth mechanism with different cooling rates. (RGG)3-PEG20 seeds are added to melted (RGG)3-PEG20 just below at 65 °C, then cooled to room temperature at different rates. FIG. 22B. Plot of endAttorney Docket NWEST-45005.601
[0064] length / total length for the long and short ends of segmented fibers. Lengths were measured by CLSM. FIG. 22C. Representative CLSM images of segmented (RGG)3-PEG20 nanofibers, following cooling at different rates. Scale bar = 10 pm.
[0065] FIG. 23. Additional CLSM images of five-segment fibers of (RGG)3-PEG20. Scale bar = 10 pm.
[0066] FIG. 24. Negative stained TEM images of (EGG)3-PEG20. Assembled at 99 °C, 500 pM, IxPB, pH 7.4, 150 mM NaCl. Scale bar = 1 pm (left) and 250 nm (right).
[0067] FIG. 25A. Selected 2d classes of (EGG)3-PEG20 from cryo-EM. Each panel has a width of 25 nm. FIG. 25B shows power spectra of respective (EGG)3-PEG202D classes.
[0068] FIG. 26A-26B show cross section analysis (right) of (EGG)3-PEG202D class. FIG. 26A. Average horizontal cross-section profile. Distance between green lines (fiber width) = 136.8 A. Distance between blue lines (width of highly structured core) = 27.2 A. Distance between orange lines (inter-beta sheet spacing) = 5.8 A. FIG. 26B. Vertical cross-section profile. Average repeat distance between intensity peaks (beta sheet spacing) = 5.0 A
[0069] FIG. 27A. Selected 2D classes of (RGG)3-PEG20 from cryo-EM. Each panel has a width of 25 nm. FIG. 27B. Power spectra of respective (RGG)3-PEG202D classes.
[0070] FIG. 28. Variable temperature fluorescence measurement of nile red with (EGG) -PEG20 during heating (solid black circle) and cooling (white circles with black edges). Tmeiting= 39 °C, Tnudeation = 16 °C. 500 pM PA, IxPB, pH 7.4, 150 mM NaCl. Sample was heated at 1 °C / min from 20 to 99 °C, held 1 minute at 99°C, then cooled 1 °C / min from 99 to 1 °C.
[0071] Experiment was run in triplicate.
[0072] FIG. 29A. Representative CLSM image of length controlled (EGG)3-PEG20 nanofibers, following self-seeded growth at 51 °C. Lv = 5.0 pm, D = 1.06. Scale bar = 10 pm. FIG. 29B Representative CLSM images of three-segment (EGG)3-PEG20 nanofibers. Left is 0.25 pM and right is 10 pM. Scale bar = 10 pm. FIG. 29C. Length statistics of three-segment (EGG)3-PEG20 nanofibers, “short”: the shorter end segment of a fiber; “long”: the longer end segment of a fiber. LA?, long=3.2 pm, Diong=1.05, LA?, short=1.13 pm, Dshort=1.37, L ?, total=5.1 pm, Dtotai=1.06 FIG. 30A Representative CLSM images of three-segment ((EGG)3-PEG20) - ((RGG)3-PEG20) - ((EGG)3-PEG20) nanofibers. Left is 0.25 pM and right is 10 pM. Scale bar = 10 pm. FIG. 30B shows length statistics of three-segment ((EGG)3-PEG20) - ((RGG)3-PEG20) -((EGG)3-PEG20) nanofibers, “short”: the shorter end segment of a fiber; “long”: the longer endAttorney Docket NWEST-45005.601
[0073] segment of a fiber. L , long = 4.6 pm, DiOng= 1.05; L , short = 1.4 pm, DShort = 1.32; L , total = 6.7 pm, Dtotal = 1.05
[0074] FIGS. 31A-31C show epresentative CLSM images of fibers used for mouse cortical neuron treatments. FIG. 31 A. E fibers ((EGG)2-PEG20). L,v = 8.8 pm, D = 1.09. FIG. 31B. R fibers ((RGG)3-PEG20). L = 8.9 pm, D = 1.06. FIG. 31C. Segmented E-R-E fibers ((EGG)2-PEG20) - ((RGG)3-PEG20) - (EGG)2-PEG20). LN = 6.9 pm, D = 1.07. Scale bar = 10 pm.
[0075] FIG. 32. Variable temperature fluorescence measurement of nile red with (EGG)2-PEG20 during heating (solid black circle) and cooling (white circles with black edges). Tmeiting = 51 °C, Tnucieation = 39 °C. 500 pM PA, IxPB, pH 7.4, 150 mM NaCl. Sample was heated at 1 °C / min from 25 to 99 °C, held 1 minute at 99°C, then cooled 1 °C / min from 99 to 25 °C.
[0076] Experiment was run in triplicate.
[0077] FIG. 33. Variable temperature fluorescence measurement of nile red with (RGG)s-PEG20 (left) or (EGG)2-PEG20 (right) during heating at lower PA concentration. Solid black circle: RFU, black cross: -d(RFU) / dT. For (RGG)3-PEG20, Tmeiting= 55 °C. For (EGG)2-PEG20, Tmeiting = 52 °C. 50 pM PA. Samples were heated at 1 °C / min in IxPB, pH 7.4, 150 mM NaCl. Experiment was run in triplicate. Melting transition for (RGG)3-PEG20 (left) was poorly defined due to low total fluorescence under these conditions.
[0078] FIG. 34. Negative stained TEM images of (EGG)2-PEG20. Assembled at 99 °C, 500 pM, IxPB, pH 7.4, 150 mM NaCl. Scale bar = 1 pm (left) and 250 nm (right).
[0079] FIG. 35A. Representative fluorescence microscopy images for live / dead assay at 48 hours post treatment. Image width = 1279 pm. FIG. 35B shows neurite length at 24 hours post treatment. Each dot is a separate image.
[0080] FIG. 36. Cell morphology at 24 hours post treatment. DAPI: blue, Tujl: green, phalloidin: red. SMI: blue. Scale bars = 50 pm.
[0081] FIG. 37. Additional images of cell morphology at 48 hours post treatment. R treatment was not imaged due to cell toxicity. DAPI: blue, Tujl: green, phalloidin: red, SMI: blue. Scale bars = 50 pm.
[0082] FIGS. 38A-38B show Sholl analysis of mouse cortical neuron morphology 48 hours post treatment. FIG. 38 A shows the number of mean intersections in control and E-R-E treated groups. FIG. 38B shows a box plot of branching index for the no treatment and the segmentedAttorney Docket NWEST-45005.601
[0083] E-R-E treatment, p «< 0.0L For no treatment, N = 58 (no. of cells); for segmented E-R-E treatment, N = 60.
[0084] FIG. 39. Additional images of nanofiber-cell interaction at 24 hours post treatment. Denoised and deconvoluted. DAPI: blue, Tujl: cyan, Cy3-labelled negatively charged fiber: green, Cy5-labelled positively charged fiber: magenta. Scale bars = 10 pm.
[0085] FIG. 40. Nanofiber-cell interaction at 48 hours post treatment. Denoised and deconvoluted. DAPI: blue, Tujl: cyan, Cy3-labelled negatively charged fiber: green, Cy5-labelled positively charged fiber: magenta. Scale bars = 10 pm.
[0086] FIG. 41. Nanofiber-cell interaction at 48 hours post treatment. Z-projections. DAPI: blue, Tujl: cyan, Cy3-labelled negatively charged fiber: green, Cy5-labelled positively charged fiber: magenta. Scale bars = 10 pm.
[0087] FIG. 42. Nanofiber-cell interaction at 48 hours post treatment. Z-projections with Cy3 (green, center column) and Cy5 (magenta, right column) channels split from DAPI and Tuj 1 (blue and cyan, left column). Nanofibers were observed to be locally concentrated along neurites, - especially in the segmented E-R-E and R treatments - despite the additional association with the surface. DAPI: blue, Tujl: cyan, Cy3-labelled negatively charged fiber: green, Cy5-labelled positively charged fiber: magenta. Scale bars = 10 pm
[0088] FIG. 43. Negative stained TEM of AAVV (C16-AAVVGRGGRGGRGG (SEQ ID NO: 15)-PEG10-PEG10) in IxPB. pH 7.4, 150 mM NaCl. assembled at 99 °C. Scale bars: left = 1pm, right = 250 nm.
[0089] FIG. 44. Variable temperature fluorescence measurement of nile red with AAVV during heating. Sample was heated at 1 °C / min in IxPB, pH 7.4, 150 mM NaCl. Experiment was run in triplicate.
[0090] FIG. 45. Representative CLSM image of AAVV nanofibers (labelled with 2.5 mol% C16-AAVVGRGGRGGRGG (SEQ ID NO: 15)-PEG10-PEG10-Cy5), following self-seeded growth at 82 °C. L,v = 1.74 pm, D = 1.78. Scale bar = 10 pm.
[0091] FIG. 46. Length statistics of segmented AAVV nanofibers. Green end segments were labelled with 2.5 mol% C16-AAVVGRGGRGGRGG (SEQ ID NO: 15)-PEG10-PEG10-Cy3. “Seeds”: pre-assembled fibers (TaSsembiy = 82 °C) used as seeds; “center”: middle segment, derived from seeds; “shorter”: the shorter end segment of a fiber; “longer”: the longer endAttorney Docket NWEST-45005.601
[0092] segment of a fiber. LA?, seeds = 1.7 pm, Dseeds = 1.78; L,v .center — 1 - 23 pm, D center — 1.99; I .V, shorter — 1.8 |im, Dshorter=2.7; L.V. longer=2.7 pm, Dlonger=2.38.
[0093] FIG. 47. Representative CLSM images of VVAA (2.5 mol% VVAA-Cy3. green) and AAVV (2.5 mol% AAVV-Cy5, magenta) nanofibers, coassembled (left) and separately assembled then mixed (right). Scale bar = 10 pm.
[0094] FIG. 48A. Selected 2D classes of AAVV from cryo-EM. First class (top left) shows supramolecular twist. FIG. 48B. ATR-FTIR of VVAA and AAVV.
[0095] FIG 49A. Negative stained TEM of (RGG)2R (C16-VVAAGRGGRGGR (SEQ ID NO: 17)) in IxPB, pH 7.4, 150 mM NaCl, assembled at 99 °C. Scale bars: left = 1pm, right = 250 nm. FIG. 49B. Variable temperature fluorescence measurement of nile red with PAs that have different lengths of PEG appended to their C-termini. Sample was heated at 1 °C / min in IxPB, pH 7.4, 150 mM NaCl. Experiment was run in triplicate.
[0096] FIG. 50A. (RGG)2R in IxPB, pH 7.4, 150 mM NaCl, annealed at 99 °C then probe sonicated. Scale bars: left = 1 pm, right = 250 nm. FIG. 50B. Representative CLSM image of (RGG)2R nanofibers, following attempted self-seeded growth at 95 °C and 500 pM PA in IxPB, pH 7.4, 150 mM NaCl. Imaged at 10 pM. Scale bar = 10 pm.
[0097] FIG. 51 A. (RGG)3-PEG30 in IxPB, pH 7.4, 150 mM NaCl, assembled at 99 °C. Scale bars: left = 1 pm, right = 250 nm. FIG. 5 IB. Representative CLSM images of (RGG)3-PEG30 nanofibers, following self-seeded growth at 77 °C (left) and 80 °C (right), 500 pM PA in IxPB, pH 7.4, 150 mM NaCl. Imaged at 0.25 pM. Scale bar = 10 pm.
[0098] FIG. 52A. Negative stained TEM of (RGG)3-PEG10 in IxPB, pH 7.4, 150 mM NaCl, annealed at 99 °C. Scale bars: left = 1pm, right = 250 nm. FIG. 52B. Negative stained TEM of (RGG)3-PEG10 in IxPB, pH 7.4, 150 mM NaCl, annealed at 99 °C, then probe sonicated. Scale bars: left = 1 pm, right = 250 nm.
[0099] FIG. 53A. Negative stained TEM images of (RGG)3-PEG20 (left) and (RGG)3-PEG10 (right) assembled at 99 °C, then probe sonicated and aged at room temperature for 24 hours. IxPB, pH 7.4, 150 mM NaCl, annealed at 99 °C. Scale bars = 250 nm. FIG. 53B.
[0100] Representative CLSM images of (RGG)3-PEG10 (with 2.5 mol% (RGG)3-PEG20-Cy3) nanofibers, following attempted self-seeded growth at 78 °C. Left is 0.25 pM and right is 10 pM. Scale bar = 10 pm.Attorney Docket NWEST-45005.601
[0101] FIG. 54A. Negative stained TEM of R3-PEG2O in IxPB, pH 7.4, 150 mM NaCl, assembled at 99 °C. Scale bars: left = 1pm, right = 250 nm. FIG. 54B. Variable temperature fluorescence measurement of nile red with R3-PEG2O during heating. Tmeiting = 52 °C. Sample was heated at 1 °C / min in IxPB, pH 7.4, 150 mM NaCl. Experiment was run in triplicate.
[0102] FIG. 55. Self-seeded assembly experiment with R3-PEG2O. CLSM images. For TaSsembiy = 75 °C: = 2.6, D = 1.28. Scale bar = 10 pm.
[0103] DEFINITIONS
[0104] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments described herein, some preferred methods, compositions, devices, and materials are described herein. However, before the present materials and methods are described, it is to be understood that this invention is not limited to the particular molecules, compositions, methodologies or protocols herein described, as these may vary in accordance with routine experimentation and optimization. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the embodiments described herein.
[0105] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. However, in case of conflict, the present specification, including definitions, will control. Accordingly, in the context of the embodiments described herein, the following definitions apply.
[0106] As used herein and in the appended claims, the singular forms “a”, “an” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a peptide amphiphile” is a reference to one or more peptide amphiphiles and equivalents thereof known to those skilled in the art, and so forth.
[0107] As used herein, the term “comprise” and linguistic variations thereof denote the presence of recited feature(s), element(s), method step(s), etc. without the exclusion of the presence of additional feature(s), element(s), method step(s), etc. Conversely, the term “consisting of’ and linguistic variations thereof, denotes the presence of recited feature(s), element(s), method step(s), etc. and excludes any unrecited feature(s), element(s), method step(s), etc., except forAttorney Docket NWEST-45005.601
[0108] ordinarily-associated impurities. The phrase “consisting essentially of’ denotes the recited feature(s), element(s), method step(s), etc. and any additional feature(s), element(s), method step(s), etc. that do not materially affect the basic nature of the composition, system, or method. Many embodiments herein are described using open “comprising” language. Such embodiments encompass multiple closed “consisting of’ and / or “consisting essentially of’ embodiments, which may alternatively be claimed or described using such language.
[0109] The term “amino acid” refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers, unless otherwise indicated, if their structures allow such stereoisomeric forms.
[0110] Natural amino acids include alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamine (Gin or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (He or I), leucine (Leu or L), Lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y) and valine (Vai or V).
[0111] Unnatural amino acids include, but are not limited to, azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, naphthylalanine (“naph”), aminopropionic acid, 2-aminobutyric acid, 4- aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine (“tBuG”), 2,4-diaminoisobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline (“hPro” or “homoP”), hydroxylysine, allo-hydroxylysine, 3-hydroxyproline (“3Hyp”), 4-hydroxyproline (“4Hyp”), isodesmosine, allo-isoleucine, N-methylalanine (“MeAla” or “Nime”), N- alkylglycine (“NAG”) including N-methylglycine, N-methylisoleucine, N- alkylpentylglycine (“NAPG”) including N-methylpentylglycine. N-methylvaline, naphthylalanine, norvaline (“Norval”), norleucine (“Norleu”), octylglycine (“OctG”). ornithine (“Orn”), pentylglycine (“pG” or “PGly”), pipecolic acid, thioproline (“ThioP” or “tPro”), homoLysine (“hLys”), and homoArginine (“hArg”).
[0112] The term “amino acid analog” refers to a natural or unnatural amino acid where one or more of the C-terminal carboxy group, the N-terminal amino group and side-chain bioactive group has been chemically blocked, reversibly or irreversibly, or otherwise modified to another bioactive group. For example, aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid; N-ethylglycine is an amino acid analog of glycine; or alanine carboxamide is anAttorney Docket NWEST-45005.601
[0113] amino acid analog of alanine. Other amino acid analogs include methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteine sulfone.
[0114] As used herein, the term “peptide” refers an oligomer to short polymer of amino acids linked together by peptide bonds. In contrast to other amino acid polymers (e.g., proteins, polypeptides, etc.), peptides are of about 50 amino acids or less in length. A peptide may comprise natural amino acids, non-natural amino acids, amino acid analogs, and / or modified amino acids. A peptide may be a subsequence of naturally occurring protein or a non-natural (artificial) sequence.
[0115] As used herein, the term “artificial” refers to compositions and systems that are designed or prepared by man, and are not naturally occurring. For example, an artificial peptide, peptoid, or nucleic acid is one comprising a non-natural sequence (e.g., a peptide without 100% identity with a naturally-occurring protein or a fragment thereof).
[0116] As used herein, a “conservative” amino acid substitution refers to the substitution of an amino acid in a peptide or polypeptide with another amino acid having similar chemical properties, such as size or charge. For purposes of the present disclosure, each of the following eight groups contains amino acids that are conservative substitutions for one another:
[0117] 1) Alanine (A) and Glycine (G);
[0118] 2) Aspartic acid (D) and Glutamic acid (E);
[0119] 3) Asparagine (N) and Glutamine (Q);
[0120] 4) Arginine (R) and Lysine (K);
[0121] 5) Isoleucine (I). Leucine (L), Methionine (M), and Valine (V);
[0122] 6) Phenylalanine (F), Tyrosine (Y), and Tryptophan (W);
[0123] 7) Serine (S) and Threonine (T); and
[0124] 8) Cysteine (C) and Methionine (M).
[0125] Naturally occurring residues may be divided into classes based on common side chain properties, for example: polar positive (or basic) (histidine (H), lysine (K), and arginine (R)); polar negative (or acidic) (aspartic acid (D), glutamic acid (E)); polar neutral (serine (S), threonine (T), asparagine (N), glutamine (Q)); non-polar aliphatic (alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M)); non-polar aromatic (phenylalanine (F), tyrosine (Y),Attorney Docket NWEST-45005.601
[0126] tryptophan (W)); proline and glycine; and cysteine. As used herein, a “semi-conservative” amino acid substitution refers to the substitution of an amino acid in a peptide or polypeptide with another amino acid within the same class.
[0127] In some embodiments, unless otherwise specified, a conservative or semi-conservative amino acid substitution may also encompass non-naturally occurring amino acid residues that have similar chemical properties to the natural residue. These non-natural residues are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include, but are not limited to, peptidomimetics and other reversed or inverted forms of amino acid moieties. Embodiments herein may, in some embodiments, be limited to natural amino acids, non-natural amino acids, and / or amino acid analogs.
[0128] Non-conservative substitutions may involve the exchange of a member of one class for a member from another class.
[0129] As used herein, the term “sequence identity” refers to the degree of which two polymer sequences (e.g., peptide, polypeptide, nucleic acid, etc.) have the same sequential composition of monomer subunits. The term “sequence similarity” refers to the degree with which two polymer sequences (e.g., peptide, polypeptide, nucleic acid, etc.) differ only by conservative and / or semiconservative amino acid substitutions. The “percent sequence identity” (or “percent sequence similarity”) is calculated by: (1) comparing two optimally aligned sequences over a window of comparison (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window, etc.), (2) determining the number of positions containing identical (or similar) monomers (e.g., same amino acids occurs in both sequences, similar amino acid occurs in both sequences) to yield the number of matched positions. (3) dividing the number of matched positions by the total number of positions in the comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window), and (4) multiplying the result by 100 to yield the percent sequence identity or percent sequence similarity. For example, if peptides A and B are both 20 amino acids in length and have identical amino acids at all but 1 position, then peptide A and peptide B have 95% sequence identity. If the amino acids at the non-identical position shared the same biophysical characteristics (e.g., both were acidic), then peptide A and peptide B would have 100% sequence similarity. As another example, if peptide C is 20 amino acids in length and peptide D is 15 amino acids in length, and 14 out of 15 amino acids in peptide D are identical to those of a portion of peptide C, then peptides C and D haveAttorney Docket NWEST-45005.601
[0130] 70% sequence identity, but peptide D has 93.3% sequence identity to an optimal comparison window of peptide C. For the purpose of calculating “percent sequence identity” (or “percent sequence similarity”) herein, any gaps in aligned sequences are treated as mismatches at that position.
[0131] Any polypeptides described herein as having a particular percent sequence identity or similarity (e.g., at least 70%) with a reference sequence ID number, may also be expressed as having a maximum number of substitutions (or terminal deletions) with respect to that reference sequence. For example, a sequence having at least Y% sequence identity (e.g., 90%) with SEQ ID NO:Z (e.g., 100 amino acids) may have up to X substitutions (e.g., 10) relative to SEQ ID NO:Z, and may therefore also be expressed as “having X (e.g., 10) or fewer substitutions relative to SEQ ID NO:Z.”
[0132] As used herein, the term “nanofiber” refers to an elongated or threadlike filament (e.g., having a significantly greater length dimension that width or diameter) with a diameter typically less than 100 nanometers. A “nanofiber” is inclusive of a “segmented nanofiber”. As used herein, a “segmented nanofiber” refers to a nanofiber comprising a positively charged peptide amphiphile segment flanked on one end by a first negatively charged peptide amphiphile segment and flanked on the other end by a second negatively charged peptide amphiphile segment. Throughout the disclosure, the term “fiber” may refer to a “nanofiber” or to a “segmented nanofiber” depending on the context.
[0133] As used herein, the term “scaffold” refers to a material capable of supporting growth and differentiation of a cell.
[0134] As used herein, the term “supramolecular” (e.g., “supramolecular complex,” “supramolecular interactions,” “supramolecular fiber,” “supramolecular polymer,” etc.) refers to the non-covalent interactions between molecules (e.g., polymers, macromolecules, etc.) and the multicomponent assemblies, complexes, systems, and / or fibers that form as a result.
[0135] As used herein, the terms “self-assemble” and “self-assembly” refer to formation of a discrete, non-random, aggregate structure from component parts; said assembly occurring spontaneously through random movements of the components (e.g. molecules) due only to the inherent chemical or structural properties and attractive forces of those components.
[0136] As used herein, the term “peptide amphiphile” refers to a molecule that, at a minimum, includes a lipophilic (hydrophobic) segment and a structural peptide segment (e.g. a P-sheetAttorney Docket NWEST-45005.601
[0137] forming peptide segment). In some embodiments, a peptide amphiphile includes a hydrophobic segment, a structural peptide segment (e.g. p-sheet forming peptide segment), and a charged peptide segment. The charged peptide amphiphile may express a net charge at physiological pH, either a net positive or negative net charge, or may be zwitterionic (i.e., carrying both positive and negative charges). In some embodiments, the charged peptide segment is positively charged. In some embodiments, the charged peptide segment is negatively charged.
[0138] As used herein and in the appended claims, the term “lipophilic moiety” or “hydrophobic moiety” refers to the moiety (e.g., an acyl, ether, sulfonamide, or phosphodiester moiety) disposed on one terminus (e.g., C-terminus, N-terminus) of the peptide amphiphile, and may be herein and elsewhere referred to as the lipophilic or hydrophobic segment or component. The hydrophobic segment should be of a sufficient length to provide amphiphilic behavior and aggregate (or nanosphere or nanofiber) formation in water or another polar solvent system.
[0139] Accordingly, in the context of the embodiments described herein, the hydrophobic component preferably comprises a single, linear acyl chain of the formula: Cn-iH2n-iC(O)- where n=2-25. In some embodiments, a linear acyl chain is the lipophilic group (saturated or unsaturated carbons), palmitic acid. However, other lipophilic groups may be used in place of the acyl chain such as steroids, phospholipids and fluorocarbons.
[0140] As used interchangeably herein, the terms “structural peptide” or “structural peptide segment” refer to a portion of a peptide amphiphile, typically disposed between the hydrophobic segment and the charged peptide segment. The structural peptide is generally composed of three to ten amino acid residues with non-polar, uncharged side chains (e.g., His (H), Vai (V), He (I), Leu (L), Ala (A), Phe (F)) selected for their propensity to form hydrogen bonds or other stabilizing interactions (e.g., hydrophobic interactions, van der Waals' interactions, etc.) with structural peptide segments of adjacent structural peptide segments. In some embodiments, nanofibers of peptide amphiphiles having structural peptide segments display linear or 2D structure when examined by microscopy and / or a-helix and / or P-sheet character when examined by circular dichroism (CD).
[0141] As used herein, the term “beta (P)-sheet-forming peptide segment” refers to a structural peptide segment that has a propensity to display -sheet-like character (e.g., when analyzed by CD). In some embodiments, amino acids in a beta ( )- sheet-forming peptide segment are selected for their propensity to form a beta-sheet secondary structure. Examples of suitableAttorney Docket NWEST-45005.601
[0142] amino acid residues selected from the twenty naturally occurring amino acids include Met (M), Vai (V), He (I), Cys (C), Tyr (Y), Phe (F), Gin (Q), Leu (L), Thr (T), Ala (A), and Gly (G) (listed in order of their propensity to form beta sheets). However, non-naturally occurring amino acids of similar beta-sheet forming propensity may also be used. Peptide segments capable of interacting to form beta sheets and / or with a propensity to form beta sheets are understood (See, e.g.. Mayo et al. Protein Science (1996). 5:1301-1315; herein incorporated by reference in its entirety).
[0143] As used herein, the term “charged peptide segment” refers to a portion of a peptide amphiphile that is rich (e.g., >50%, >75%, etc.) in charged amino acid residues, or amino acid residue that have a net positive or negative charge under physiologic conditions. A charged peptide segment may be acidic (e.g., negatively charged / anionic), basic (e.g.. positively charged / cationic), or zwitterionic (e.g., having both acidic and basic residues).
[0144] In some embodiments, the charged peptide segment is a negatively-charged peptide segment. A negatively charged peptide segment refers to a peptide sequence of a peptide amphiphile that comprises one or more amino acid residues that have side chains displaying carboxylic acid side chains (e.g., Glu (E), Asp (D), or non-natural amino acids). In some embodiments, the negatively-charged peptide segment contains one or more additional (e.g., non-acidic) amino acid residues. Non-natural amino acid residues, or peptidomimetics with acidic side chains could be used, as will be evident to one ordinarily skilled in the art.
[0145] In some embodiments, the charged peptide segment is a positively-charged peptide segment. A positively-charged peptide segment refers to a peptide sequence of a peptide amphiphile that comprises one or more amino acid residues that have side chains displaying positively-charged acid side chains (e.g., Arg (R), Lys (K), His (H), or non-natural amino acids, or peptidomimetics). A positively-charged peptide segment may optionally contain one or more additional (e.g., non-basic) amino acid residues. Non-natural amino acid residues with basic side chains could be used, as will be evident to one ordinarily skilled in the art.
[0146] As used herein, the term “biocompatible” refers to materials and agents that are not toxic to cells or organisms. In some embodiments, a substance is considered to be “biocompatible” if its addition to cells in vitro results in less than or equal to approximately 10% cell death, usually less than 5%. more usually less than 1%.Attorney Docket NWEST-45005.601
[0147] As used herein, “biodegradable” as used to describe the polymers, hydrogels, and / or wound dressings herein refers to compositions degraded or otherwise “broken down” under exposure to physiological conditions. In some embodiments, a biodegradable substance is a broken down by cellular machinery, enzymatic degradation, chemical processes, hydrolysis, etc. In some embodiments, a wound dressing or coating comprises hydrolyzable ester linkages that provide the biodegradability.
[0148] As used herein, the term “PEG domain” refers to a domain comprising at least one polyethlene glycol (PEG) or derivative thereof. The term “polyethylene glycol” or “PEG” as used interchangeably herein refers to a polyether compound typically denoted by the structure H-(O-CH2-CH2)n-OH. As denoted by the structure, a PEG may comprise a number of repeating ethylene glycol (O-CH2-CH2) subunits, denoted by “n”. A single ethylene glycol subunit of PEG has a molecular weight of approximately 44 Daltons. Therefore, the molecular weight of the PEG polymer depends on the number (n). In some embodiments, the term PEG domain may refer to a domain comprising at least one PEG containing 10-30 repeating ethylene glycol subunits (e.g. H-(O-CH2-CH2)I-20-OH.). For example, the PEG may contain 10, 20, or 30 repeating ethylene glycol subunits (e.g. H-(0-CH2-CH2)IO-OH). The term “PEG” also includes PEG derivatives, or PEGs coupled to other moieties.
[0149] As used herein, the phrase “physiological conditions” relates to the range of chemical (e.g., pH, ionic strength) and biochemical (e.g., enzyme concentrations) conditions likely to be encountered in the intracellular and extracellular fluids of tissues. For most tissues, the physiological pH ranges from about 7.0 to 7.4.
[0150] As used herein, the terms “treat,” “treatment,” and “treating” refer to reducing the amount or severity of a particular condition, disease state or symptoms thereof, in a subject presently experiencing or afflicted with the condition or disease state. The terms do not necessarily indicate complete treatment (e.g., total elimination of the condition, disease, or symptoms thereof). "Treatment,” encompasses any administration or application of a therapeutic or technique for a disease (e.g., in a mammal, including a human), and includes inhibiting the disease, arresting its development, relieving the disease, causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process.
[0151] As used herein, the terms “prevent,” “prevention,” and preventing” refer to reducing the likelihood of a particular condition or disease state from occurring in a subject not presentlyAttorney Docket NWEST-45005.601
[0152] experiencing or afflicted with the condition or disease state. The terms do not necessarily indicate complete or absolute prevention. For example, “prevention” refers to reducing the likelihood of a condition or disease state occurring in a subject not presently experiencing or diagnosed with the condition or disease state. In order to “prevent” a condition or disease state, a composition or method need only reduce the likelihood of the condition or disease state, not completely block any possibility thereof. "Prevention,” encompasses any administration or application of a therapeutic or technique to reduce the likelihood of a disease developing (e.g., in a mammal, including a human). Such a likelihood may be assessed for a population or for an individual.
[0153] As used herein, the terms “co-administration” and “co-administering” refer to the administration of at least two agent(s) or therapies to a subject (e.g.. a PA nanofiber and one or more therapeutic agents). In some embodiments, the co-administration of two or more agents or therapies is concurrent. In other embodiments, a first agent / therapy is administered prior to a second agent / therapy. Those of skill in the art understand that the formulations and / or routes of administration of the various agents or therapies used may vary. The appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents or therapies are co-administered, the respective agents or therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents or therapies lowers the requisite dosage of a potentially harmful (e.g., toxic) agent(s), and / or when co-administration of two or more agents results in sensitization of a subject to beneficial effects of one of the agents via co-administration of the other agent.
[0154] DETAILED DESCRIPTION
[0155] Herein, length-controlled peptide amphiphile assembles were created with precisely segmented domains of opposite charge. The peptide amphiphile assemblies herein were shown to have dimensions (e.g. lengths) comparable to the diameter of cells. The precise control over the supramolecular assembly of the PA systems herein is enabled primarily by PEGylated molecules which serve as protecting groups that maintain living fibril ends in a dormant state in the absence of monomer. This phenomenon works in synergy with the presence of a highly ordered core that provides a strong driving force for further supramolecular growth. TheAttorney Docket NWEST-45005.601
[0156] controlled growth required for precision is undermined by structural heterogeneity among the assemblies. Specifically, this precision is no longer achieved when changes in the structural peptide sequence yield filament morphologies that are not flat but instead twist with variable pitch. The assemblies herein have an inherent directionality in their structure that manifests as asymmetric growth from the two ends of a fibril.
[0157] Supramolecular polymers with segmented charge architectures are shown herein to greatly enhance growth of neurites and maintain cell viability, without having to use specific bioactive signals. In contrast, negatively charged assemblies are ineffective at stimulating growth, while positively charged ones are toxic. The inclusion of a shorter positively charged segment between two negatively charged ones electrostatically anchors the assemblies to the cells, forming a localized, dynamic scaffold with ability to capture ECM proteins (e.g. that bind to the negatively charged peptide amphiphile segments) that stimulate neuronal maturation. These results demonstrate that the precise arrangement of electrostatic charge in cell-scale supramolecular constructs can drastically change functional outcomes. Interestingly, in spite of the highly ordered core that leads to precision, the structures investigated maintain some dynamic character along their edges. Supramolecular motion at the nanoscale has been shown to improve bioactivity of assemblies. Thus, in the segmented assemblies reported here, it is likely that both order and dynamics work synergistically to give the observed enhanced biological effects. Furthermore, in traditional hydrogel scaffolds components aggregate to create bulk networks to either support cells mechanically or to signal their receptors. The systems described herein may be as large as billion-dalton assemblies with cell length dimensions that operate mostly by interacting intimately with individual neurons or other cells to optimize bioactivity. They function either in vitro or in vivo and derive specificity from the use of epitopes conjugated to their monomers. In non-biological functions, the very large assemblies could be used to build open networks on surfaces or in hierarchical 3D structures.
[0158] In some aspects, provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are negatively charged PAs, e.g. PAs wherein the amino acid in a repeating XGG subunit, as described below, is a negatively charged amino acid such as glutamic acid (E). In some embodiments, provided herein are positively charged PAs, e.g. PAs wherein the amino acid in a repeating XGG subunit, as described below, is a positively charged amino acid such asAttorney Docket NWEST-45005.601
[0159] arginine (R). Tn some aspects, provided herein are nanofibers comprising the peptide amphiphiles described herein. In some embodiments, provided herein is a nanofiber comprising (a) a positively charged peptide amphiphile segment comprising one or more positively charged peptide amphiphiles described herein, and (b) a negatively charged peptide amphiphile segment comprising one or more negatively charged peptide amphiphiles described herein. In some embodiments, the nanofiber comprises a positively charged peptide amphiphile segment flanked on one end by a first negatively charged peptide amphiphile segment and flanked on the other end by a second negatively charged peptide amphiphile segment. In some embodiments, provided herein are methods of use of the PAs and nanofibers disclosed herein.
[0160] In some embodiments, the peptide amphiphile molecules and compositions of the embodiments described herein are synthesized using preparatory techniques well-known to those skilled in the art, preferably, by standard solid-phase peptide synthesis, with the addition of a fatty acid in place of a standard amino acid at the N-terminus (or C-terminus) of the peptide, in order to create the lipophilic segment (although in some embodiments, alignment of nanofibers is performed via techniques not previously disclosed or used in the art (e.g., extrusion through a mesh screen). Synthesis typically starts from the C-terminus, to which amino acids are sequentially added using either a Rink amide resin (resulting in an -NH2 group at the C-terminus of the peptide after cleavage from the resin), or a Wang resin (resulting in an -OH group at the C-terminus). Accordingly, some embodiments described herein encompass peptide amphiphiles having a C-terminal moiety that may be selected from the group consisting of -H, - OH, -COOH, -CONH2, and -NH2.
[0161] In some embodiments, peptide amphiphiles comprise a hydrophobic segment (i.e. a hydrophobic tail) linked to a peptide. In some embodiments, the peptide comprises a structural peptide segment. In some embodiments, the structural peptide segment is a hydrogen-bondforming segment, or beta-sheet-forming segment.
[0162] In some embodiments, the peptide amphiphile further comprises linker or spacer segments for adding solubility, flexibility, distance between segments, etc. In some embodiments, the spacer segment comprises peptide and / or non-peptide elements.
[0163] The lipophilic or hydrophobic segment is typically incorporated at the N- or C-terminus of the peptide after the last amino acid coupling, and is composed of a fatty acid or other acid that is linked to the N- or C-terminal amino acid through an acyl bond. In aqueous solutions, PA
[0164] T1Attorney Docket NWEST-45005.601
[0165] molecules may self-assemble (e.g., into cylindrical micelles (a.k.a., nanofibers)) to bury the lipophilic segment in their core. In some embodiments, PAs may coassemble into a nanofiber. In some embodiments, the structural peptide undergoes intermolecular hydrogen bonding to form beta sheets that orient parallel to the long axis of the micelle.
[0166] In some embodiments, compositions described herein comprise PA building blocks that in turn comprise a hydrophobic segment and a peptide segment. In certain embodiments, a hydrophobic (e.g., hydrocarbon and / or alkyl / alkenyl / alkynyl tail, or steroid such as cholesterol) segment of sufficient length (e.g., 2 carbons, 3 carbons, 4 carbons, 5 carbons, 6 carbons, 7 carbons, 8 carbons, 9 carbons, 10 carbons, 11 carbons, 12 carbons, 13 carbons, 14 carbons, 15 carbons, 16 carbons, 17 carbons, 18 carbons, 19 carbons, 20 carbons, 21 carbons, 22 carbons, 23 carbons, 24 carbons. 25 carbons, 26 carbons, 27 carbons. 28 carbons, 29 carbons, 30 carbons or more , or any ranges there between.) is covalently coupled to peptide segment (e.g., a peptide comprising a segment having a preference for beta-strand conformations or other supramolecular interactions) to yield a peptide amphiphile molecule. In some embodiments, a plurality of such PAs will self-assemble in water (or aqueous solution) into a nanostructure (e.g., nanofiber). In various embodiments, the relative lengths of the peptide segment and hydrophobic segment result in differing PA molecular shape and nanostructural architecture. For example, a broader peptide segment and narrower hydrophobic segment results in a generally conical molecular shape that has an effect on the assembly of PAs (See, e.g., J. N. Israelachvili Intermolecular and surface forces; 2nd ed.; Academic: London San Diego, 1992; herein incorporated by reference in its entirety). Other molecular shapes have similar effects on assembly and nanostructural architecture.
[0167] In some embodiments, to induce self-assembly of an aqueous solution of peptide amphiphiles, the pH of the solution may be changed (raised or lowered) or multivalent ions, such as calcium, or charged polymers or other macromolecules may be added to the solution.
[0168] In some embodiments, the hydrophobic segment is a non-peptide segment (e.g., alkyl / alkenyl / alkynyl group). In some embodiments, the hydrophobic segment comprises an alkyl chain (e.g., saturated) of 4-25 carbons (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25), fluorinated segments, fluorinated alkyl tails, heterocyclic rings, aromatic segments, pi-conjugated segments, cycloalkyls, oligothiophenes etc. In some embodiments, the hydrophobic segment comprises an acyl / ether chain (e.g., saturated) of 2-30Attorney Docket NWEST-45005.601
[0169] carbons (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30). In some embodiments, the hydrophobic segment comprises an alkyl or an acyl chain C8-C24.
[0170] In some embodiments, PAs comprise one or more peptide segments. Peptide segments may comprise natural amino acids, modified amino acids, unnatural amino acids, amino acid analogs, peptidomimetics, or combinations thereof. In some embodiments, peptide segment comprise at least 50% sequence identity or similarity (e.g., conservative or semi-conservative) to one or more of the peptide sequences described herein.
[0171] In some embodiments, peptide amphiphiles comprise a structural peptide segment. In some embodiments, the structural peptide segment is a beta-sheet-forming segment. In some embodiments, the structural peptide segment has a total propensity for forming p-sheet conformations of 4 or more. For example, in some embodiments the structural peptide segment has a total propensity for forming p-sheet conformations of at least 4, at least 4.1, at least 4.2, at least 4.3, at least 4.4, at least 4.5, at least 4.6, at least 4.7. at least 4.8, at least 4.9, at least 5.0, at least 5.1, at least 5.2, at least 5.3, at least 5.4, at least 5.5, at least 5.6, at least 5.7, at least 5.8, at least 5.9, or at least 6.
[0172] The total propensity for forming P-sheet conformations may be calculated as the sum of the propensity for forming P-sheet conformations of each amino acid in the structural peptide segment. The propensity of each amino acid for forming p-sheet conformations and methods for calculating the same are described in, for example, Fujiwara, K., Toda, H. & Ikeguchi, M.
[0173] Dependence of a-helical and P-sheet amino acid propensities on the overall protein fold type. BMC Struct Biol 12, 18 (2012), the entire contents of which are incorporated herein by reference. Exemplary values are shown in Table 1, below. For the purposes of calculating the total propensity for forming p-sheet conformations of the structural peptide segment, the value shown in the “total residues” column from table 1 for each amino acid is added together. For example, for an VVAA (SEQ ID NO: 1) structural peptide segment, the total propensity for forming P-sheet conformations is 2 + 2 + .75 + .75 = 5.5. The structural peptide segment may comprise any suitable number and combination of amino acids to achieve a total propensity for forming P-sheet conformations of at least 4.
[0174] Table 1. Amino acid Propensities for P-sheet conformationsAttorney Docket NWEST-45005.601
[0175] Amino Acid Exposed Residues Buried Residues Total Residues V 2.31 1.57 2.00
[0176] I 2.02 1.39 1.79
[0177] L 1.18 0.93 1.15
[0178] M 1.01 0.84 1.01
[0179] P 0.49 0.42 0.40
[0180] A 0.48 0.72 0.75
[0181] C 1.24 1.07 1.36
[0182] F 1.50 1.10 1.4
[0183] Y 1.71 1.12 1.37
[0184] W 1.90 0.91 1.23
[0185] Q 0.96 0.82 0.72
[0186] s 0.86 0.85 0.81
[0187] T 1.58 1.08 1.21
[0188] N 0.71 0.76 0.63
[0189] H 1.15 0.98 0.99
[0190] D 0.61 0.76 0.55
[0191] K 1.14 0.98 0.76
[0192] E 0.89 0.86 0.65
[0193] R 1.27 0.82 0.85
[0194] G 0.41 0.81 0.67
[0195]
[0196] In some embodiments, the structural peptide segment (e.g. P-sheet-forming segment) is rich in one or more of H, I, L, F, V, G, and A residues. In some embodiments, the structural peptide segment (e.g. -sheet-forming segment) comprises an alanine- and valine-rich peptide segment (e.g., A3V3 (SEQ ID NO: 9), V2A4(SEQ ID NO: 10). V3A3 (SEQ ID NO: 11), V2A2(SEQ ID NO: 1), V4A2 (SEQ ID NO: 12)) or other combinations of V and A residues, etc.). In some embodiments, the P-sheet-forming segment comprises 2-6 amino acid residues and has a total propensity for forming beta-sheet conformations of 4 or more. In some embodiments, the P-sheet-forming segment comprises 4 or more consecutive A and / or V residues, or conservativeAttorney Docket NWEST-45005.601
[0197] or semi-conservative substitutions thereto. Tn some embodiments, the P-sheet-forming segment comprises V2A2 (SEQ ID NO: 1).
[0198] In some embodiments, the P-sheet-forming segment has a total propensity for forming beta-sheet conformations of 4 or more and produces nanofibers having a flat morphology, as opposed to a twisted morphology. “Flat” nanofibers are also referred to as “untwisted” nanofibers. In some embodiments, the P-sheet-forming segment has a total propensity for forming beta- sheet conformations of 4 or more and produces twisted nanofibers having a consistent pitch length. In some embodiments, the P-sheet-forming segment has a total propensity for forming beta-sheet conformations of 4 or more and produces twisted nanofibers having a consistent twist frequency.
[0199] The “pitch length” of a nanofiber refers to the distance required for the fiber to complete one full 360° rotation. In some embodiments, the pitch length of a nanofiber herein is between 1 to 10,000 nm (e.g. 1 to 10,000 nm, 10 to 1000 nm, 250 to 750 nm, 300 to 500 nm, 40 to 300 nm). Generally, the “pitch length” of a nanofiber is consistent across the length of the nanofiber, e.g. the pitch length for a rotation in one location on the nanofiber does not vary significantly from the pitch length for a rotation in another section of the nanofiber. The “twist frequency” of a nanofiber refers to the number of times the nanofiber completes a full 360° rotation in over a unit length. A “consistent pitch length” indicates that in a population of nanofibers produced from the same peptide amphiphile having a given structural peptide segment, the pitch length of each nanofiber varies by less than 10% from the pitch length of each other nanofiber in the population. The “pitch length” and “twist frequency” of a twisted nanofiber are inversely related and as such, a “consistent” pitch length also indicates that the nanofibers have a “consistent” twist frequency, e.g. a twist frequency that varies by less than 10% in the population of nanofibers. In contrast, the results herein demonstrate that beta-sheet segments that produce twisted nanofibers having a variable pitch length (and thus a variable twist frequency) do not experience the desired controlled growth. A “variable pitch length” indicates that in a population of nanofibers produced from the same peptide amphiphile having a given structural peptide segment, the pitch length in one or more nanofibers varies by more than 10% (and thus the twist frequency also varies by more than 10%) compared to that of one or more other nanofibers in the population. For example, in the population of nanofibers nanofiber A has a pitch length A, nanofiber B has a pitch length B, and pitch length A and B vary by more than 10%. NanofiberAttorney Docket NWEST-45005.601
[0200] morphology, e.g. whether a nanofiber is flat, twisted, has a consistent pitch length or a variable pitch length, etc., can be verified by a suitable technique, for example electron microscopy including TEM, cryo-EM, etc.
[0201] In some embodiments, peptide amphiphiles comprise a charged peptide segment. The charged peptide segment may be positively charged or negatively charged. In some embodiments, the charged peptide segment comprises one or more neutral amino acid residues and one or more positively charged amino acid residues, resulting in an overall positively charged peptide segment. In some embodiments, the charged peptide segment comprises one more neutral amino acid residues and one or more negatively charged amino acid residues, resulting in an overall negatively charged peptide segment. Exemplary neutral amino acid residues include glycine, alanine, leucine, isoleucine, valine, phenylalanine, proline, methionine, serine, threonine, tyrosine, cysteine, glutamine, asparagine and tryptophan.
[0202] In some embodiments, the charged peptide segment comprises one or more repeating XGG units, where X is a positively charged amino acid or a negatively charged amino acid. In some embodiments, X being a positively charged amino acid yields a positively charged peptide segment, whereas X being a negatively charged amino acid yields a negatively charged peptide segment, hr some embodiments, the charged peptide segment comprises 2 to 20 repeating XGG units (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeating XGG units). In some embodiments, the charged peptide segment comprises 2 to 10 repeating XGG units. In some embodiments, the charged peptide segment comprises 2 to 4 repeating XGG units.
[0203] In some embodiments, the charged peptide segment is a positively charged peptide segment wherein X is arginine (R). lysine (K) or histidine (H). In some embodiments, X is arginine. In some embodiments, the positively charged peptide segment comprises one or more repeating RGG units (e.g. 2, 3, 4, 5, 6, 7. 8, 9, 10, 11, 12, 13, 14. 15, 16, 17, 18, 19, or 20 repeating RGG units). In some embodiments, the positively charged peptide segment comprises 2 to 20 repeating RGG units. In some embodiments, the positively charged peptide segment comprises 2 to 10 repeating RGG units. In some embodiments, the positively charged peptide segment comprises 2 to 4 repeating RGG units. In some embodiments, the positively charged peptide segment comprises (RGG)a (SEQ ID NO: 2).
[0204] In some embodiments, the charged peptide segment is a negatively charged peptide segment wherein X aspartic acid (D) or glutamic acid (E). In some embodiments, X is glutamicAttorney Docket NWEST-45005.601
[0205] acid. In some embodiments, the negatively charged peptide segment comprises one or more repeating EGG units. In some embodiments, the positively charged peptide segment comprises 2 to 20 repeating EGG units (e.g. 2, 3, 4. 5, 6, 7. 8, 9. 10. 11. 12. 13. 14, 15, 16, 17, 18, 19, or 20 repeating EGG units). In some embodiments, the positively charged peptide segment comprises 2 to 10 repeating EGG units. In some embodiments, the negatively charged peptide segment comprises 2 to 4 repeating EGG units. In some embodiments, the negatively charged peptide segment comprises (EGG)3 (SEQ ID NO: 3).
[0206] In some embodiments, the peptide amphiphile comprises a PEG domain. A PEG domain refers to a domain comprising at least one polyethlene glycol (PEG) or derivative thereof. PEG refers to a polyether compound typically denoted by the structure H-(O-CH2-CH2)n-OH. As denoted by the structure, a PEG may comprise a number of repeating ethylene glycol (O-Clh-CH2) subunits, denoted by “n”. In some embodiments, the PEG domain comprises at least one PEG containing 10-30 repeating ethylene glycol subunits (e.g. H-(O-CH2-CH2)I-20-OH.). For example, the PEG may contain 10-30, 11-29, 12-28, 13-27, 14-26, 15-25, 16-24, 17-23, 18-22, 19-21, or 20 repeating ethylene glycol subunits (e.g. H-(0-CH2-CH2)io-OH). The PEG may be conjugated to other suitable moieties to impart the desired characteristics to the PA described herein. In some embodiments, the PEG domain is attached to the charged peptide segment.
[0207] In some embodiments, peptide amphiphiles comprise a spacer or linker segment. In some embodiments, the peptide amphiphile comprises a linker between the structural peptide segment (e.g. P-sheet forming peptide segment) and the charged peptide segment. In some embodiments, the linker segment is a non-peptide linker. In some embodiments, the spacer or linker segment provides a reactive group (e.g., alkene, alkyne, azide, thiol, maleimide etc.) for functionalization of the PA. In some embodiments, the spacer or linker is a substantially linear chain of CH2, O, (CH2)2O, O(CH2)2, NH, and C=O groups (e.g., CH2(O(CH2)2)2NH, CH2(O(CH2)2)2NHCO(CH2)2CCH, etc.). In some embodiments, a spacer or linker further comprises additional bioactive groups, substituents, branches, etc. In some embodiments, the linker segment is a single glycine (G) residue. In some embodiments, the linker segment is a tripeptide linker (e.g. GSG).
[0208] Suitable peptide amphiphiles for use in the materials herein, as well as methods of preparation of PAs and related materials, amino acid sequences for use in PAs. and materials that find use with PAs, are described in the following patents: U.S. Pat. No. 9,044,514; U.S. Pat. No.Attorney Docket NWEST-45005.601
[0209] 9,040,626; U.S. Pat. No. 9,011,914; U.S. Pat. No. 8,772,228; U.S. Pat. No. 8,748,569 U.S. Pat. No. 8,580,923; U.S. Pat. No. 8,546,338; U.S. Pat. No. 8,512,693; U.S. Pat. No. 8,450,271; U.S. Pat. No. 8,236.800; U.S. Pat. No. 8,138,140; U.S. Pat. No. 8,124,583; U.S. Pat. No. 8.114,835; U.S. Pat. No. 8,114,834; U.S. Pat. No. 8,080,262; U.S. Pat. No. 8,076,295; U.S. Pat. No.
[0210] 8,063,014; U.S. Pat. No. 7,851,445; U.S. Pat. No. 7,838,491; U.S. Pat. No. 7,745,708; U.S. Pat. No. 7,683,025; U.S. Pat. No. 7.554,021; U.S. Pat. No.7, 544.661; U.S. Pat. No. 7,534,761; U.S. Pat. No. 7,491,690; U.S. Pat. No. 7,452,679; U.S. Pat. No. 7,371,719; U.S. Pat. No. 7,030,167; all of which are herein incorporated by reference in their entireties.
[0211] The characteristics (e.g., shape, rigidity, hydrophilicity, etc.) of a PA supramolecular structure depend upon the identity of the components of a peptide amphiphile (e.g., lipophilic segment, acidic segment, structural peptide segment, targeting moiety, etc.). For example, nanofibers, nanospheres, intermediate shapes, and other supramolecular structures are achieved by adjusting the identity of the PA component parts. In some embodiments, characteristics of supramolecular nanostructures of PAs are altered by post-assembly manipulation (e.g., heating / cooling, stretching, etc.).
[0212] In some embodiments, the peptide amphiphile comprises: (a) a hydrophobic tail comprising an alkyl chain of 8-24 carbons; (b) a P-sheet forming peptide segment (e.g., comprising V2A2 (SEQ ID NO: 1)); (c) a charged peptide segment comprising one or more repeating XGG units, and (d) a PEG domain (e.g., a PEG comprising 10-30 repeating ethylene glycol subunits).
[0213] In some embodiments, a positively charged peptide amphiphile comprises: (a) a hydrophobic tail comprising an alkyl chain of 8-24 carbons; (b) a P-sheet forming peptide segment (e.g., comprising V2A2 (SEQ ID NO: 1)); (c) a charged peptide segment comprising one or more repeating RGG units (e.g. 2 to 10 repeating RGG units, 2 to 4 repeating RGG units), and (d) a PEG domain (e.g., a PEG comprising 10-30 repeating ethylene glycol subunits). In some embodiments, a positively charged peptide amphiphile comprises: (a) a hydrophobic tail comprising an alkyl chain of 8-24 carbons; (b) a P-sheet forming peptide segment (e.g., comprising V2A2 (SEQ ID NO: 1); (c) a charged peptide segment comprising one or more repeating RGG units (e.g. 2 to 10 repeating RGG units, 2 to 4 repeating RGG units), (d) a PEG domain (e.g.. a PEG comprising 10-30 repeating ethylene glycol subunits), and (e) a linker (e.g.Attorney Docket NWEST-45005.601
[0214] a single glycine residue) that attaches the 0-sheet forming peptide segment to the charged peptide segment.
[0215] In some embodiments, a negatively charged peptide amphiphile comprises: (a) a hydrophobic tail comprising an alkyl chain of 8-24 carbons; (b) a P-sheet forming peptide segment (e.g., comprising V2A2 (SEQ ID NO: 1); (c) a charged peptide segment comprising one or more repeating EGG units (e.g. 2 to 10 repeating EGG units, 2 to 4 repeating EGG units), and (d) a PEG domain (e.g., a PEG comprising 10-30 repeating ethylene glycol subunits). In some embodiments, the peptide amphiphile comprises: (a) a hydrophobic tail comprising an alkyl chain of 8-24 carbons; (b) a P-sheet forming peptide segment (e.g., comprising V2A2 (SEQ ID NO: 1); (c) a charged peptide segment comprising one or more repeating EGG units (e.g. 2 to 10 repeating EGG units, 2 to 4 repeating EGG units), (d) a PEG domain (e.g., a PEG comprising 10-30 repeating ethylene glycol subunits), and (e) a linker (e.g. a single glycine residue) that attaches the p-sheet forming peptide segment to the charged peptide segment.
[0216] In some embodiments, provided herein are nanofibers and nanostructures assembled from any combination of the peptide amphiphiles described herein. In some embodiments, a nanofiber is prepared by the self-assembly of the PAs described herein.
[0217] In some embodiments, provided herein is a segmented nanofiber comprising a positively charged peptide amphiphile segment comprising one or more positively charged peptide amphiphiles described herein. In some embodiments, provided herein is a nanofiber comprising a negatively charged peptide amphiphile segment comprising one or more negatively charged peptide amphiphiles described herein.
[0218] In some embodiments, provided herein are segmented nanofibers comprising oppositely charged peptide amphiphile segments along their length. In some embodiments provided herein is a segmented nanofiber comprising a positively charged peptide amphiphile segment and at least two negatively charged peptide amphiphile segments. In some embodiments, the segmented nanofiber comprises a positively charged peptide amphiphile segment flanked on one end by a first negatively charged peptide amphiphile segment and flanked on the other end by a second negatively charged peptide amphiphile segment. This flanking on both ends can also be referred to as a segmented nanofiber comprising a positively charged peptide amphiphile segment “surrounded by” the two negatively charged peptide amphiphile segments. As used herein, the positively charged peptide amphiphile being “surrounded by” or “flanked by” the atAttorney Docket NWEST-45005.601
[0219] least two negatively charged peptide amphiphiles indicates that in the segmented nanofiber structure, the positively charged peptide amphiphile is between the two negatively charged peptide amphiphiles, such that one negatively charged peptide amphiphile is bound to a first end of the positively charged peptide amphiphile and the other negatively charged peptide amphiphile is bound to a second end of the positively charged peptide amphiphile.
[0220] In some embodiments, a segmented nanofiber comprises more than one positively charged peptide amphiphile segment. In some embodiments, the segmented nanofiber comprises more than two negatively charged peptide amphiphile segments, hr some embodiments, the segmented nanofiber comprises at least one positively charged peptide amphiphile segment that is flanked on one end by a first negatively charged peptide amphiphile segment and flanked on the other end by a second negatively charged peptide amphiphile segment (e.g. surrounded by two negatively charged peptide amphiphile segments), and comprises at least one positively charged peptide amphiphile segment that is not flanked at both ends by two negatively charged peptide amphiphile segments. For example, the segmented nanofiber may comprise a terminal positively charged peptide amphiphile segment, e.g. a positively charged peptide amphiphile segment at the end of the nanofiber. As another example, the segmented nanofiber may comprise a terminal positively charged peptide amphiphile segment at each end of the nanofiber. In some embodiments, the segmented nanofiber comprises a negatively charged peptide amphiphile segment positioned between two positively charged peptide amphiphile segments. In some embodiments, the segmented nanofiber comprises at least one terminal positively charged peptide amphiphile segment flanked on only one side by a negatively charged peptide amphiphile segment, which negatively charged peptide amphiphile segment flanks one end of a distinct positively charged peptide amphiphile segment. For example, an exemplary segmented nanofiber containing more than one positively charged peptide amphiphile segment is shown in FIG. 2G.
[0221] In some embodiments, the positively charged peptide amphiphile segment, or the multiple positively charged peptide amphiphile segments if present in a segmented nanofiber, act as an anchor to attach the entire segmented nanofiber to a negatively charged cell membrane. The combined action of many such nanofibers could provide a local, closely associated supramolecular scaffold for cell adhesion and growth.Attorney Docket NWEST-45005.601
[0222] Tn some embodiments, the segmented nanofiber has a length of 0.1 m to 100 pm. For example, in some embodiments, the segmented nanofiber has a length of 0.1 pm to 100 pm, 0.5 pm to 75 pm, 1 pm to 50 pm, 5 pm to 45 pm, 10 pm to 40 pm, or 20 pm to 30 pm. In some embodiments, the segmented nanofiber has a total length of at least 5 pm. In some embodiments, the nanofiber has a total length of at least 10 pm. In some embodiments, the segmented nanofiber has a total length of at least 20 pm. In some embodiments, the nanofiber has a total length of 5 to 35 pm. In some embodiments, the positively charged peptide amphiphile makes up less than 30%, less than 20%, or less than 10% of the nanofiber by length. In some embodiments, the two negatively charged peptide amphiphiles are asymmetric in length. In some embodiments, the length of the first negatively charged peptide amphiphile segment is at least 50% greater than the length of the second negatively charged peptide amphiphile segment. In some embodiments, the length of the first negatively charged peptide amphiphile segment is at least double the length of the second negatively charged peptide amphiphile segment.
[0223] In some embodiments, the segmented nanofibers herein are formed by self-assembly through a controlled nucleation-growth mechanism to generate segmented and asymmetric nanofibers with precise dimensions. A nucleation-growth mechanism refers to a mechanism in which a controlled number of small segments, referred to as nuclei, begin to grow at the same time and at the same rate until assembly into the full nanofiber is complete. As shown in the accompanying Examples, the nucleation-growth process can be controlled by temperature to generate nanofibers having the desired length. In some embodiments, the nuclei are generated by sonicating peptide amphiphile materials and applying a suitable melting temperature. The resulting nuclei may be unmelted material. Segmented nanofiber assembly can then be directed via annealing at a suitable temperature (e.g. above the melting temperature). The length of the resulting segmented nanofibers can be controlled by the annealing temperature, thereby achieving precise control over the length of the resulting nanofibers. This one-step, self-seeded method of making length-controlled PA nanofibers is exceptionally straightforward and consistent, and compatible with biologically relevant aqueous conditions at high molecular concentrations. In some embodiments, the segmented nanofibers assemble by interactions between the beta- sheet forming segments of the peptide amphiphiles, which promote extension of the nanofiber as shown in FIG. 2D.Attorney Docket NWEST-45005.601
[0224] In some embodiments, provided herein are compositions comprising a peptide amphiphile or a segmented nanofiber herein. The composition may further comprise one or more pharmaceutically acceptable carriers. For example, the composition may further comprise one or more pharmaceutically acceptable carriers for delivery to a cell or a subject.
[0225] The PAs, segmented nanofibers, and compositions described herein find use in a variety of methods. In some embodiments, provided herein is a method comprising contacting a cell with a composition as described herein. In some embodiments, the cell is a neuron. In some embodiments, the PAs, segmented nanofibers, and composition herein can be used as a scaffold to promote cell growth, maturation, and / or morphology. For example, the nanofibers herein, in particular segmented nanofibers comprising positively charged and negatively charged peptide amphiphiles, are shown to significantly improve neurite growth and morphology. In some embodiments, the segmented nanofibers herein comprise at least one positively charged peptide amphiphile segment that electrostatically anchors the nanofiber to a cell membrane and two or more negatively charged peptide amphiphile segments that can bind to proteins in the ECM, thus promoting cell growth, maturation, and morphology due to the actions of these bound proteins.
[0226] The PAs, nanofibers, and compositions herein therefore find use in regenerative medicine. For example, the PAs, nanofibers, and compositions can be applied to a cell (e.g. a neuron) or a subject to promote one or more features of neuron health and / or viability (e.g. neurite outgrowth, maturation, cell signaling) after injury. The term “injury” is used in the broadest sense and is inclusive of any damage or disfunction of cells (e.g. neurons) that can occur due to a variety of factors including disease (e.g. neurodegenerative disease), aging, trauma, ischemic injury (e.g. stroke), and the like.
[0227] In some embodiments, the compositions described herein are formulated for delivery to a subject. In some embodiments, the compositions are administered parenterally. The term “parenteral” refers to any suitable non-oral route of administration, including subcutaneous, intramuscular, intravenous, intrathecal, intracisternal, intraarterial, intraspinal, intraepidural, intradermal, and the like. The PA compositions herein can be administered as the sole active agent or in combination with other pharmaceutical agents. For example, the compositions can be administered in combination with other agents for regenerative therapy in a subject.
[0228] In some aspects, provided herein is a system comprising a cell and a segmented nanofiber herein, wherein the positively charged peptide amphiphile segment is electrostatically anchoredAttorney Docket NWEST-45005.601
[0229] to the cell membrane, and wherein the positively charged peptide amphiphile segments bind to extracellular proteins in proximity to the cell. In some embodiments, the cell is a neuron. In some embodiments, electrostatic interactions between the positively charged peptide segment and the cell membrane anchors the nanofiber to the cell across its length. In some embodiments, at least 90% of the entire length of the segmented nanofiber is anchored to the cell. In some embodiments, at least 95% of the entire length of the segmented nanofiber is anchored to the cell. In some embodiments, at least 98% of the entire length of the segmented nanofiber is anchored to the cell. A segmented nanofiber or portion thereof being “anchored” to the cell membrane refers to a nanofiber or portion thereof that is retained, via electrostatic interactions between the positively charged peptide amphiphile domain and the cell membrane, within 0.5 pm of the surface of the cell membrane across the length of the segmented nanofiber or portion thereof. In some embodiments, the segmented nanofiber is retained within 400 nm, 300 nm, 200 nm, or 100 nm of the cell membrane across the length of the segmented nanofiber. In some embodiments, the negatively charged peptide amphiphile segments bind extracellular matrix protein which then induce their effects on the cell due to the proximity of the negatively charged peptide segments to the cell membrane. In some embodiments, the length of the segmented nanofiber is about 5 to about 30 microns in length, and at least 90% of the entire length of the segmented nanofiber is anchored to the cell. The length of the nanofibers herein shown to be comparable to the size of a cell, as such anchoring the length of the segmented nanofiber to the cell promotes bioactivity of ECM proteins across the entire cell. As such, the segmented nanofibers herein promote bioactivity on the cell without requiring a specific bioactive epitope to be present on the nanofiber itself.
[0230] EXAMPLES
[0231] Example 1
[0232] Soft nanomaterials designed to integrate with and affect biological tissues by mirroring their spatial inhomogeneity remain difficult to synthesize. Driven by beta-sheet interactions between peptide amphiphiles, size-defined nanofibers with precisely controlled asymmetric onedimensional architectures were synthesized. Nanofibers with oppositely charged segments along their lengths enhanced the growth of neurons, as the positive domains anchored the fibers to the negatively charged cell membrane and dramatically increased cell-fiber interactions. The designAttorney Docket NWEST-45005.601
[0233] rules for the peptide amphiphile sequences that allow the controlled one-dimensional synthesis of nanofibers were also uncovered. Surprisingly, appending polyethylene glycol to the termini of the peptide sequences stabilized the ends of the nanofibers, facilitating their living supramolecular polymerization.
[0234] Results and discussion
[0235] Self-seeded growth
[0236] (RGG)3-PEG20 (C16-VVAAGRGGRGGRGG (SEQ ID NO: 4)-PEG10-PEG10is a peptide amphiphile (PA) consisting of a C 16 tail, a short beta-sheet forming sequence, a charged region, and a pegylated C-terminus (Fig. 1A). (RGG)3-PEG20 was designed with the goal of promoting a controlled and discrete nucleation- growth mechanism of self-assembly to form nanofibers that could further undergo living supramolecular polymerization. Key to the design was inhibiting two phenomena that could prevent this. First, PEG was appended to the C-terminus of the PA to reduce non-specific fiber-fiber interactions that would potentially interfere with the discrete nucleation-growth of individual fibers. And second, a flexible, sterically bulky charged region was used, placed adjacent to the short beta-sheet region to increase interfacial curvature and encourage controlled one-dimensional supramolecular polymerization (rather than the formation of two-dimensional, planar morphologies). (RGG)3-PEG20 - at 500 pM in phosphate buffer (PB, pH 7.4) with 150 mM sodium chloride - formed long nanofibers following heating at 1 °C / min to 99 °C (TaSsembiy = 99 °C), holding for 1 hour, then cooling at 1 °C / min to 25 °C. The fibers had a uniform width without any regular twisting, as shown by transmission electron microscopy (TEM) (FIG. 7A). When (RGG)3-PEG20 was coassembled with 2.5 % mole percent of a dye labelled PA ((RGG)3-PEG20-Cy3, Supplementary Table 1), very long fibers were visualized using confocal laser scanning microscopy (CLSM) (FIG. 7B).
[0237] (RGG)3-PEG20 fibers were found to undergo a melting transition from fibers to spherical micelles centered around 68 °C. Variable temperature (VT) fluorescence using nile red as a probe for the hydrophobic environment of the fiber cores showed a sharp decrease in fluorescence upon heating (corresponding to the Tmeiting) (Fig. IB). A broader increase of fluorescence during cooling centered around 53 °C (corresponding to the TnUcieation) was also observed (FIG. 8A). Small angle x-ray scattering measurements below and above the TmeitingAttorney Docket NWEST-45005.601
[0238] confirmed the observed transition corresponded to a change in morphology from nanofibers to small spherical micelles (Fig. 1C). Variable temperature polarized optical microscopy (POM) on a higher concentration sample also showed a loss in birefringence corresponding to beta-sheet melting, centered at 79 °C (FIG. 8B).
[0239] (RGG)3-PEG20 spontaneously self-assembled into length-controlled nanofibers following assembly at specific temperatures above the Tmeiting. with lengths increasing as Tassembiy increased (Fig. ID, F). As observed and measured using CESM and atomic force microscopy, small increases in Tassembiy gave dramatic increases in number average fiber lengths (LJV), with each sample showing very low dispersity in length (D). Assembling at 80 °C (heating at 1 °C / min to 80 °C, holding for 1 hour, then cooling at 1 °C / min to 25 °C) yielded fibers of 2.6 pm (D = 1.02), while assembling at 85 °C gave fibers of 20.3 pm (D = 1.04) - a 21-fold increase in length (FIG. ID, FIG. IF). Atomic force microscopy images are shown in FIG. 9. The bulk mechanical properties (e.g. viscosities) of the solutions were significantly altered due to fiber length alone (FIG. 10).
[0240] The generation of nanofibers with very little dispersity in length suggested a nucleationgrowth mechanism of self-assembly, in which a controlled number of nuclei begin to grow at the same time and at the same rate until the assembly is complete. Differences in the number of nuclei would result in differences in nanofiber length: less nuclei would give fewer, longer fibers, and more nuclei would give a greater number of shorter fibers. In this case, length is controlled by Tassembiy, indicating that the number of nuclei is dependent on the assembly temperature.
[0241] Potentially, the nuclei are unmelted material - as Tassembiy increases, the proportion of unmelted material decreases, and therefore the number of nuclei also decreases. Prior to annealing, all samples were bath sonicated for five minutes, giving a polydisperse mixture of very short fibers and particles (FIG. 11). An unmelted proportion of this material would act as nuclei to seed the growth of the longer fibers observed upon cooling (Fig. IE). In this way, the system can be described as self-seeded. This one-step, self-seeded method of making length-controlled PA nanofibers is exceptionally straightforward and consistent, and compatible with biologically relevant aqueous conditions at high molecular concentrations.
[0242] Nanofiber length-control through assembly temperature was an irreversible process. (RGG)3-PEG20 nanofibers assembled at 80 °C (Ew= 2.7 pm, D = 1.01) were reassembled atAttorney Docket NWEST-45005.601
[0243] either 78, 80, or 82 °C. When reassembled at a lower temperature (78 °C) than the initial TaSsembiy (80°C), nanofiber length did not become shorter (LJV = 2.7 pm, D = 1.03); however, reassembling at a higher temperature (82°C) gave longer fibers (L,v = 4.6 pm, D = 1.02) (FIG. 12). As heating and cooling did not generate shorter fibers than those present in the initial state, new nuclei must not form during heating and cooling. The melting and elongation mechanisms are likely microscopic reversals of each other, with shortening and lengthening occurring from the ends of the fibers. Further, the melting transition was observed to increase in temperature and broaden as fiber length increased, providing additional evidence that the number of ends controls the kinetics of the assembly (FIG. 13).
[0244] Molecular mixing of the fibers was limited in its extent and stable over time. When separately assembled (RGG)3-PEG20 fibers of different lengths and labelled with either Cy3 or Cy5 ((RGG)3-PEG20-Cy5) were mixed, Forster resonance energy transfer (FRET) efficiency increased over the course of ca. 32 hours before stabilizing (FIG. 14). CLSM analysis after 6 days showed some mixing of Cy3 and Cy5 within fibers, but the populations were clearly distinct not only by fluorescence but also length (FIG. 15). A standard curve of FRET efficiency as a function of mixing found that the fibers were 10 % mixed (0.1 mol fraction of minor component) (FIG. 16). These results show that there is a small mobile fraction of molecules that are dynamic and can exchange between fibers, but the extent of mixing is limited by the presence of a large immobile fraction.
[0245] Living supramolecular polymerization of segmented fibers
[0246] To further test the proposed nucleation- growth mechanism of (RGG)3-PEG20 selfassembly, the system was manually seeded (rather than self-seeded) to generate length-controlled nanofibers. Pre-assembled (RGG)3-PEG20 fibers were probe sonicated to generate “seeds” (FIG.
[0247] 17). which were added to melted (RGG)3-PEG20 (“melt”) that had been pre-heated at 99 °C and cooled to 65 °C (“melt”). Adding the seeds at 65 °C - below the Tmeiting, but above the TnUcieation -ensured the seeds did not melt and acted as nuclei for the elongation of fibers upon cooling (FIG.
[0248] 18). Varying the melt / seed ratio allowed linear control over the nanofiber lengths. This is the first- time seeded growth with precise length-control has been demonstrated using C16 peptide amphiphiles.Attorney Docket NWEST-45005.601
[0249] Segmented PA nanofibers with different fluorescent dyes localized to different regions were synthesized via living supramolecular polymerization (Fig. 2A). The temperature-controlled self-seeded method was first employed to generate short nanofiber seeds of Cy5-labelled (RGG)3-PEG20 (Tassembiy = 78 °C), which were added to Cy3-labelled (RGG)3-PEG20 melt to initiate the living supramolecular polymerization. A high concentration of melted material (~ 1 mM in aqueous solution) was used for all experiments to ensure the protocol was robust and generated useful amounts of nanofibers in a solution suitable for biological applications. Varying the melt to seed ratio resulted in fibers with discrete segments of controllable lengths: higher melt / seed values gave fibers with longer Cy3-labelled segments (Fig.
[0250] 2A, FIG. 19). As per the manually seeded growth experiments, the total fiber lengths had a linear relationship to the melt to seed ratio (Fig. 2B). A yield of three-segment fibers of 93 % was achieved (FIG. 20).
[0251] Surprisingly, the segmented fibers grew asymmetrically in all cases. By CLSM, the segmented fibers displayed one long end and one short end (Fig. 2A). Statistical analysis of fibers with the greatest melt to seed ratio (11 to 1) showed that the long end was on average 3.1 times the length of the short end and that both long and short ends had a very narrow length distribution (Fig. 2C). Very long segmented, asymmetric fibrils with total lengths over 30 pm and very low dispersity were synthesized using this technique (FIG. 2H) The low dispersity in lengths suggested that despite the asymmetric growth, the supramolecular polymerization was a living process on both ends. Wide angle x-ray scattering (WAXS) experiments performed on (RGG)3-PEG20 nanofibers show clear evidence of a highly ordered beta-sheet structure (Fig. 4F). The chiral nature of the amino acids combined with the ordered packing within the nanofibers naturally leads to directionality in the beta-sheet. As a result, the microscopic surfaces of each end of the nanofibers will be distinct and may have different amino acid side chains exposed (Fig. 2D). It then follows that the living supramolecular polymerization has a forwards and backwards direction with different rates of growth - the more favorable direction results in the long ends, while the less favorable gives the short.
[0252] Seeding temperature was varied to further investigate the mechanism of growth. When seeds were added at 68 °C (above the original seeding temperature of 65 °C), little change was observed; however, decreasing the seeding temperature resulted in higher dispersity in length of the short ends (Fig. 2E, FIG. 21). The lowest seeding temperature tested (60 °C) caused a drasticAttorney Docket NWEST-45005.601
[0253] increase of dispersity in the lengths of the short ends, with many fibers notably displaying unidirectional growth only. The stochastic nature of elongation on the short ends suggests there is an activation energy barrier for its initiation at lower temperatures (in addition to its lower rate). The steric impacts of PEG may play a role in this phenomenon. Seeding at 65 °C but cooling at a very fast rate gave a similar result to seeding at 60 °C (FIG. 22). Long ends remained uniform in length regardless of the seeding temperature or cooling rate.
[0254] Multiple steps of the asymmetric living supramolecular polymerization were carried out to synthesize peptide amphiphile nanofibers with five discrete segments (Fig. 2F, FIG. 23). Five-segment fibers were synthesized by seeding Cy5 labelled (RGG)3-PEG20 melt with previously synthesized three-segment fibers. The three-segment fibers were synthesized using a melt / seed ratio of 11, while the five-segment fiber synthesis used a melt / seed ratio of 2. Again, asymmetric growth was observed: five segment fibers had two short segments on one end and two long segments on the other, with the original seed segment in between. The segments of each fiber were measured sequentially, starting from the end with the shortest end-segment (segments A to E), which statistically validated the observed asymmetry (Fig. 2G). Yield of five segment fibers was 57 %, with the second largest population being one-segment fibers (29 %), formed from undesirable secondary nucleation of the melt (FIG. 20). Further optimization of the multi-step synthesis may be achieved by adjusting the salt concentration of the additional steps, as this was higher in the five-segment experiment relative to the three, due to the reduced melt / seed ratio.
[0255] Charge architecture
[0256] The identity of the charged amino acids in the PA sequence were varied, ultimately allowing the synthesis of PA nanofibers with segments along their lengths displaying opposite charges. Positively-charged nanoparticles can display cytotoxicity due to their strong interaction with biological membranes. As an alternative, the potential for a negatively charged analogue of (RGG)3-PEG20 to undergo the self-seeded nucleation-growth mechanism was tested: (EGG)s-PEG20 (C16-VVAAGEGGEGGEGG (SEQ ID NO: 5)-PEG10-PEG10, Fig. 3A). As seen by negative stained TEM, (EGG)3-PEG20 formed long fibers when assembled at 99 °C, with a uniform width that resembled (RGG)3-PEG20 (FIG. 24). By cryogenic electron microscopy (cryo-EM), two prominent fiber orientations were observed: a thinner electron dense one, and a wider more diffuse orientation, likely showing a ribbon-like structure laying on its edge or itsAttorney Docket NWEST-45005.601
[0257] face, respectively (Fig. 3B). The 2D classes showed a zipper-like microscopic structure: at least two distinct rows of highly ordered beta-sheets (displaying a characteristic 5.0 A spacing) were present in the center of the structure running parallel to the long fiber axis (Fig. 3C, FIG. 25, FIG. 26). The width of the highly structured core was 27 A, with regions of lower electron density extending out to a width of 13.7 nm (likely corresponding to less ordered regions of peptide and PEG) (Supplementary Fig. 24). This unstructured corona may contain a small fraction of weakly associated PA molecules, explaining the observed mobile fraction. 2D classes with such clearly defined beta-sheets were not easily resolved for (RGG)s-PEG20, due to diffuse electron density surrounding the fibers possibly due to arginine-phosphate interactions (FIG. 27A-27B).
[0258] VT fluorescence measurement of (EGG)3-PEG20 revealed a sharp melting transition centered around 39 °C (FIG. 28). Assembling Cy3-labelled (EGG)3-PEG20 fibers at 51 °C gave length-controlled nanostructures (LA? = 5.0 pm, D = 1.06) as seen by CLSM (FIG. 29A). Living supramolecular polymerization was then performed using Cy5-labelled (EGG)3-PEG20 core segments (Tanncai = 48 °C) as seeds to grow Cy3-labelled (EGG)3-PEG20 (Supplementary Table 1) melt (Fig. 4D, FIG. 29B)). Clearly segmented fibers were once again observed by CLSM with asymmetric end lengths (Lv i(in= 3.2 pm, Diong = 1.05; LA?, short = 1.1 pm, DShort = 1.37), demonstrating that the mechanism is consistent regardless of the fiber charge (FIG. 29C). As indicated by cryo-EM, the highly ordered beta-sheet core likely controls the supramolecular structure, allowing variable amino acid composition within the charged regions without impacting assembly.
[0259] Short (RGG)3-PEG20 length-controlled fibers (positively charged, Cy5-labelled) previously assembled at 78 °C were then used as seeds to grow negatively charged (EGG)3-PEG20 (Cy3-labelled) ends (Fig. 4E, FIG. 30). The synthesis was successful: segmented fibers were obtained with asymmetric end lengths; however, in this case the nanofibers possessed controlled regions with opposite charge along their lengths. No apparent aggregation of the fibers due to electrostatic interactions was observed (Fig. 4E, right), likely due to the steric bulk provided by the PEG, which provides a barrier region of PEG20 + PEG20 between two fibers.
[0260] Enhanced neurite outgrowth using segmented charge architecturesAttorney Docket NWEST-45005.601
[0261] Fibers with oppositely charged segments should be incredibly useful to engineer controlled fiber-fiber, fiber-cargo, and fiber-surface interactions. Although positively charged nanoparticles can be cytotoxic, their strong interaction with cellular membranes highlights their potent bioactive potential. Exploiting this interaction while limiting total exposure would be a beneficial feature for bioactive materials. A small positively charged segment - on a predominantly negatively charged fiber - would act as an anchor to attach the entire fiber to a negatively charged cell membrane. The combined action of many fibers acting in this way would provide a local, closely associated supramolecular scaffold for cell adhesion and growth.
[0262] PA nanofibers with oppositely charged segments along their lengths were found to significantly improve neurite growth and morphology. Three fiber charge architectures were tested: completely negatively charged, glutamic acid-based fibers (E): completely positively charged, arginine-based fibers (R); and fibers with a small positive segment surrounded by negative segments (segmented E-R-E) (Fig. 4A, FIG. 31). To improve stability at physiological temperatures and biologically relevant lower PA concentrations. (EGG)2-PEG20 (C16-VVAAGGGEGGEGG (SEQ ID NO: 14)-PEG10-PEG10) was used as the negative species, in which one glutamic acid residue was removed from (EGG)3-PEG20 (FIG. 32-34). For segmented E-R-E, the positive segment made up just 12.5 mole % of the entire fiber. Lengths for each architecture were circa 7 to 9 pm (FIG. 31). Cortical mouse neurons grown on poly-D-lysine coated surface were treated with 45 pM PA in solution. A live / dead assay confirmed that R is cytotoxic; however, the segmented E-R-E showed no toxicity compared to the no treatment condition (Fig. 4B, FIG. 35 A). Neurite growth was measured in real-time and a significant increase in length was observed for the segmented E-R-E treatment compared to all other conditions (Fig. 4C). The difference was most significant at 24 hrs (pcO.OOl, FIG. 35B), but was maintained at 48 hours (Fig. 4D). Importantly, in addition to the increased neurite length, the segmented E-R-E treatment resulted in a distinct cell morphology compared to the no treatment and the E treatment at 24 and 48 hours (Fig. 4E, FIG. 36, FIG. 37). Neurons treated with segmented E-R-E displayed a high degree of neurite branching and overall cell complexity (as shown by scholl, FIG. 38A-38B).
[0263] Segmented E-R-E fibers were found to beneficially interact with neurons to a much greater extent than negatively charged E fibers. Mouse cortical neurons were treated withAttorney Docket NWEST-45005.601
[0264] fluorescently labelled E, R, and segmented E-R-E fibers. Tn all treatments, positively charged fibers or segments were labelled with Cy5 (magenta), while negatively charged fibers or segments were labelled with Cy3 (green). After 24 and 48 hours, the cells were imaged and substantial differences in the cell-fiber interactions were observed. Negatively charged E treatment fibers alone showed low interaction with the cells or with the substrate, suggesting that the fibers mostly remained freely diffusing in solution (Fig. 4F, FIGS. 39-42). Conversely, segmented E-R-E fibers were observed to be highly associated with the neurons and the substrate, with greater localization occurring specifically on the neurites (Fig. 4G, FIGS. 39-42). Importantly, the negatively charged segments of the segmented E-R-E treatment were observed concentrating along the neurons and their neurites to a much greater extent than the E treatment alone, confirming that the positively charged segments are driving association of the entire fiber with the cell (Fig. 42). Fibers were seen aligning along the neurites, as well as branching off and forming neurite-neurite and neurite-substrate connections (Fig. 4G, FIGS. 39-42). In this way, the segmented E-R-E fibers acted as a structural growth medium - a localized, reconfigurable ECM. The positively charged R fibers also showed high interaction with the cells. The absence of any adjacent negatively charged fiber segments to dilute the strength of fiber-cell interactions in the R treatment could possibly contribute to cell death and poor neurite outgrowth via membrane disruption (FIGS. 39-42).
[0265] The fiber-cell interactions directed by microdomains of adjacent positive and negative charge emulates the topography of adhesive contacts between cell membranes and the ECM. By concentrating a low total amount of positively charged fiber into micron-scale domains, the nanomaterials become inhomogeneous and provide distributed regions for cell adhesion. The adjoining negatively charged surfaces not only prevent cytotoxicity by limiting membrane disruption, they also balance the adhesion, potentially preventing excessively strong contacts between the neurite and the nanomaterial that may inhibit growth cone migration and branching.
[0266] Impact of amino acid sequence
[0267] The fundamental mechanistic details of the (RGG)3-PEG20 system were further investigated to generalize and apply them to a wider variety of PA molecules and applications. The sequence of the amino acids in the beta-sheet region was found to be important forAttorney Docket NWEST-45005.601
[0268] controlling the nucleation-growth mechanism. Switching the sequence from VVAA (as in (RGG)3-PEG20, referred to as VVAA in this section for clarity) to AAVV (C16-AAVVGRGGRGGRGG (SEQ ID NO: 15)-PEG10-PEG10) also gave long fibers by TEM (Fig.
[0269] 5A, FIG. 43). Melting curve analysis of AAVV showed a gradual transition - suggesting a less uniform melting mechanism - and the self-seeding method at 82 °C (above the peak of the derivative melting curve) resulted in a highly polydisperse population of fibers (Ljv = 1.74 pm, D = 1.78) (FIG. 44-45). This polydisperse population was then used as the seed segments for living supramolecular polymerization (Fig. 5B). Asymmetric end growth was again observed from the seed segments; however, the populations of both the long and short ends were polydisperse in length (FIG. 46). The asymmetry supported the hypothesis that the ends of the fibers grow at different rates, but the polydispersity in the end lengths further suggested another degree of variation: different seeds grow at different rates. A non-uniform population of seeds could explain this observation.
[0270] Importantly, AAVV did not undergo living supramolecular polymerization from preformed seed segments of VVAA. Melted AAVV was seeded with VVAA at 65 °C and the seeds remained unchanged while a polydisperse population of PA2 fibers formed (Fig. 5C). The incompatibility between the VVAA seeds and the AAVV melt indicated a mismatch in the fiber structure, likely due to the packing of the sidechains in the beta sheet region. Conversely, when VVAA and AAVV were coassembled together by heating to 99 °C and cooling, a high degree of mixing was seen by confocal (FIG. 47). This suggests that even though a thermodynamically favorable mixture of VVAA and AAVV is possible, the initial seed structure is key for controlling any subsequent living supramolecular polymerization.
[0271] Cryogenic electron microscopy (cryo-EM) was used to confirm the impacts of amino acid sequence on the nanofiber assembly. Similarly to negative-stained TEM, VVAA gave very uniform, untwisted fibers by cryo-EM (Fig. 5D). In contrast, AAVV gave thin, twisted ribbons by cryo-EM (Fig. 5D, FIG. 48A). Pitch length varied between AAVV fibers, suggesting variation in molecular packing, while VVAA showed no twist (Fig. 5D, E). Previous work with PAs has shown that dispersity in pitch length can be traced back to inhomogeneity in the nuclei structure - nuclei with slightly different widths and beta-sheet twist angles may have comparableAttorney Docket NWEST-45005.601
[0272] energies, depending on the amino acid sequence. Nuclei with different molecular packing would be expected to have different elongation rates (as observed), and the resultant fiber population should also have a broader melting transition (as observed). Attenuated total reflectance (ATR) Fourier transform infrared spectroscopy (FTIR) showed a slight shift in beta sheet peak position, indicating a weaker interaction for AAVV compared to VVAA (FIG. 48B). Nuclei structure is likely determined by beta sheet interactions and side-chain packing. Reducing the strength of the beta sheet and increasing the influence of the side-chains on the nuclei structure may flatten the energy landscape, as hydrophobic side-chain interactions are less directional than hydrogen bonds.
[0273] Role of PEG and the charged sequence
[0274] The pegylated termini of the PAs were also found to play a role in the living supramolecular polymerization mechanism. Assembled (EGG)3-PEG20 was imaged by TEM immediately following probe sonication and very short fiber segments were observed (Fig. 6B). After 24 hours aging, the sample showed no change in morphology. In contrast, (EGG)2E (C16-VVAAGEGGEGGE (SEQ ID NO: 16)) - an analogue of (EGG)3-PEG20 with the PEG and terminal two glycine monomers absent -gave longer fibers than PA2 immediately following sonication, and after an additional 24 hours aging the fibers had grown to be very long (Fig. 6A, B). These results indicate that fiber lengths are not stable in the absence of the pegylated PA termini. The structural discontinuity at the nanofiber ends exposes the hydrophobic interior to the aqueous solution, giving the molecules at the end a relatively higher energy than those within the fiber. The stable, very short fibers formed by (EGG)3-PEG20 indicate that the fiber ends are unusually low in energy, potentially due to the PEG being long enough to cover their otherwise exposed hydrophobic surfaces (Fig. 6C). PEG has been shown to preferentially dehydrate and interact with hydrophobic surfaces, supporting the possibility that it may form a protective layer on the hydrophobic nanofiber ends.
[0275] By TEM, (RGG)2R (C16-VVAAGRGGRGGR (SEQ ID NO: 17)) gave wide, thin ribbons composed of many smaller fibers joined edge-to-edge and showed a broader melting transition at higher temperatures (FIG. 49). Sonication yielded shorter assemblies of the same edge-to-edge ribbons - rather than distinct very short fibers - and attempted self-seeding resultedAttorney Docket NWEST-45005.601
[0276] in aggregated fibers by CLSM (Fig. 6D, FIG. 50). The unidimensional aggregation seen by TEM suggested a specific mechanism of fiber-fiber interaction, possibly due to phosphate-driven arginine- arginine cross-linking (Fig. 6D). (RGG R demonstrated another important function of the PEG segments: the prevention of fiber- fiber interactions that likely interfere with a controlled nucleation-growth mechanism. Fiber-fiber interactions can also impact the applicability of the nanostructures, as larger bundled or laminated materials will interface with biological membranes and macromolecules in a less consistent way compared to individual, well-dispersed fibers.
[0277] The impact of the length of the PEG region on the nucleation- growth mechanism and the extent of fiber-fiber interactions was then investigated. (RGG)3-PEG30 (C16-VVAAGRGGRGGRGG (SEQ ID NO: 4)-PEG10-PEG10-PEG10), with a longer PEG region compared to (RGG)3-PEG20 gave stable seeds and could also undergo self-seeded growth to give length-defined fibers (FIG. 51). Shortening the length of PEG segment to just one PEG10 unit ((RGG)3-PEG10, C16-VVAAGRGGRGGRGG (SEQ ID NO: 4)-PEG10) also resulted in very short seeds following sonication; however, some elongation was observed following 24 hours (FIG. 52, FIG. 53A). When self-seeding was attempted, fiber-fiber interactions were observed by CLSM, and fiber length was uncontrolled (FIG. 53B). Maintaining the PEG segment but removing the glycine residues within the charged region gave R3-PEG20 (C16-VVAAGRRR (SEQ ID NO: 13)-PEG10-PEG10). R3-PEG20 formed nanofibers as seen by TEM, with a reduced melting temperature and a slightly broader transition compared to (RGG)3-PEG20 (FIG. 54). Self-seeded growth of R3-PEG2O yielded some control over length, but with a higher dispersity than was observed with to (RGG)3-PEG20 or to (EGG)3-PEG20 (T assembly — 75 °C: L,v = 2.6, D = 1.28, FIG. 55). Furthermore, circular dichroism (CD) indicated that the removal of the PEG or glycine residues drastically reduced the random coil component of the peptide conformation, which likely decreases interfacial curvature, facilitating dispersity in fiber widths; and increases the propensity of structured fiber-fiber interactions (Fig. 6E).
[0278] Conclusion
[0279] Through deliberate molecular design and in-depth characterization and control over the self-assembly mechanism, the synthesis of precisely structured and chemically inhomogeneousAttorney Docket NWEST-45005.601
[0280] PA nanofibers was achieved. Nanofibers with segmented charge architectures along their lengths were shown to interact directly with cortical neurons without displaying cytotoxicity, greatly enhancing neurite outgrowth and complexity. The simple addition of a small positively-charged region within the nanofibers completely altered how they behave in a biological context. The sequence design parameters of the PA molecules were explored and the remarkable impact of PEG in facilitating the inhomogeneous nanofiber synthesis by stabilizing the fiber lengths was revealed.
[0281] PA molecules that can undergo controlled nucleation-growth and living supramolecular polymerization can be identified by several characteristics (Fig. 5F): a sharp melting transition indicating a uniform population of microstructures; a sharp cross-peak in the WAXS indicating low variation in 2D structure; a combination of beta-sheet and random coil secondary structure in CD; and the presence of a pegylated terminus to stabilize the lengths of the fibers. When a PA is particularly unsuitable, its morphology will also present as a twisted fiber with variation in pitch lengths. Understanding these design rules will enable a broader exploration of how the peptide sequence space and the variation in charge architecture of the nanofibers can be optimized to produce a potent therapy for spinal cord regeneration.
[0282] Table 1. Sequences and synthesis notes of peptide amphiphiles (PAs) used.
[0283] PA Sequence (V: valine, A: alanine, G: Notes
[0284] glycine, R: arginine, E: glutamic acid; all
[0285] PAs have C-terminus amide).
[0286] (RGG)3-PEG20, C16-VVAAGRGGRGGRGG (SEQ ID
[0287] VVAA NO: 4)-PEG10-PEG10
[0288] (RGG)3-PEG20- C16-VVAAGRGGRGGRGG (SEQ ID Cy3-DBCO coupled Cy3, VVAA-Cy3 NO: 4)-PEG10-PEG10-K(az)-Cy3 through azidolysine (K(az)).
[0289] (RGG)3-PEG20- C16-VVAAGRGGRGGRGG (SEQ ID Cy5-DBCO coupled Cy5, VVAA-Cy5 NO: 4)-PEG10-PEG10-K(az)-Cy5 through azidolysine
[0290] (K(az)).
[0291]
[0292] Attorney Docket NWEST-45005.601
[0293] (EGG)3-PEG20 C16-VVAAGEGGEGGEGG (SEQ ID
[0294] NO: 5)-PEGl 0-PEG 10
[0295] (EGG)2-PEG20- C16-VVAAGGGEGGEGG (SEQ ID NO: Cy3-DBCO coupled Cy3 14)-PEG 10-PEG 10-K(az)-Cy3 through azidolysine (K(az)). Used as Cy3 label for all negatively- charged fibers.
[0296] (EGG)2-PEG20- C16-VVAAGGGEGGEGG (SEQ ID NO: Cy5-DBCO coupled Cy5 14)-PEG 10-PEG 10-K(az)-Cy5 through azidolysine (K(az)). Used as Cy5 label for all negatively- charged fibers.
[0297] (EGG)2-PEG20 C16-VVAAGGGEGGEGG (SEQ ID NO:
[0298] 14)-PEG10-PEG 10
[0299] AAVV C16-AAVVGRGGRGGRGG (SEQ ID
[0300] NO: 15)-PEG10-PEG10
[0301] AAVV-Cy3 C16-AAVVGRGGRGGRGG (SEQ ID Cy3-DBCO coupled NO: 15)-PEG10-PEG10-K(az)-Cy3 through azidolysine (K(az)).
[0302] AAVV-Cy5 C16-AAVVGRGGRGGRGG (SEQ ID Cy5-DBCO coupled NO: 15)-PEG10-PEG10-K(az)-Cy5 through azidolysine (K(az)).
[0303] (EGG)2E C16-VVAAGEGGEGGE (SEQ ID NO:
[0304] 16)
[0305] (RGG)2R C16-VVAAGRGGRGGR (SEQ ID NO:
[0306] 17)
[0307] (RGG)3-PEG30 C16-VVAAGRGGRGGRGG (SEQ ID
[0308] NO: 4)-PEG10-PEG10-PEG10
[0309] (RGG)3-PEG10 C16-VVAAGRGGRGGRGG (SEQ ID
[0310] NO: 4)-PEG10
[0311]
[0312] Attorney Docket NWEST-45005.601
[0313] R3-PEG20 C16-VVAAGRRR (SEQ ID NO: 13)- PEG10-PEG10
[0314]
[0315] Materials and Methods
[0316] General materials
[0317] General sample preparation of peptide amphiphile nanofibers
[0318] Stock solutions of peptide amphiphiles (PA) were prepared at 1 mM in HFIP and stored at -20 °C. Required volumes of PA stocks were taken (and mixed if necessary, e.g. with dye-labelled equivalent PA) and dried in air before lOxPB pH 7.4 buffer, 1 M NaCl, and H2O were added to give an aqueous solution of 500 pM PA, IxPB pH 7.4, and 150 mM NaCl (unless stated otherwise). Samples were vortexed, briefly bath sonicated, and then lyophilized. Once dry the samples were resuspended in H2O. PA samples were bath sonicated for five minutes and vortexed immediately before assembling as per the relevant section below.
[0319] Self-seeding of peptide amphiphile nanofibers
[0320] Samples were prepared prior to assembly as per the general method, with 4 mol% of the fluorescently labelled species. To anneal, samples were heated at 1 °C / min from 25 °C to the desired Tassembiy, held for 1 hour, then cooled at 1 °C / min back to 25 °C.
[0321] Generation of seeds
[0322] 200 pL of 500 pM PAI sample with 4 mol% Cy3-labelled, previously annealed at 99 °C, was placed in a 0.5 mL plastic tube and probe sonicated for 2 minutes at 30% amplitude.
[0323] Manually seeded growth of PAI fibers
[0324] PAI seeds were generated as per the Generation of seeds method. 20 pL of unannealed PAI (with 4 mol% dye-labelled) at 500 pM in IxPB pH 7.4 and 150 mM NaCl was quickly heated to 99 °C, held for 1 hour, and then quickly cooled to 65 °C to give a melted PA solution. An aliquot of seed solution was pre-heated at 65 °C for 30 seconds before 1 pL was added to the melted PAI solution, pipette mixed, then cooled at 1 °C / min to 25 °C. The concentration of the seed solution was adjusted (through dilution with IxPB, pH 7.4, 150 mM NaCl) before adding to the melt solution to ensure the addition of 1 pL regardless of the melt / seed value.Attorney Docket NWEST-45005.601
[0325] Synthesis of three-segment PAI fibers
[0326] Seed segments of the fibers were generated by assembling PAI with 4 mol% Cy5 at 78 °C using the self-seeding method. To prepare the melt, PAI with 4 mol% Cy3 was mixed in HFIP, dried in air, further dried by lyophilization, then redissolved in ultrapure water at 1 mM. The melt was bath sonicated for five minutes, quickly heated to 99 °C, held for one hour, then quickly cooled to 65 °C. The seed segments with Cy5 cores were preheated at 65 °C for thirty seconds, the added at the desired melt / seed ratio to the melt at 65 °C. The solution was cooled at 1 °C / min to 25 °C. In some experiments the core segments were added at different temperatures and the solution cooled at different rates to study the impact, as described in the text.
[0327] Synthesis of five-segment PAI fibers
[0328] Melt was prepared as per the synthesis of three-segment fibers using Cy5 instead of Cy3. lOx PB pH 7.4 and 1 M NaCl was added to the three-segment fibers to be used at seed to bring the buffer and salt concentration to IxPB pH 7.4 and 150 mM NaCl. The melt was heated at 99 °C for one hour, then quickly cooled to 65 °C. The three-segment fiber seeds were pre-heated at 65 °C for 30 seconds then added to the melt. The sample was then cooled 1 °C / min to 25 °C.
[0329] Synthesis of three-segment PA2 fibers
[0330] Three-segment PA2 fibers were prepared as per the PAI fibers with several changes. Seed segments were prepared at a Tassembiy of 49 °C instead of 78 C, the melt was dissolved in IxPB pH 7.4 with 150 mM NaCl instead of water, and the system was seeded at 34 °C instead of 65 °C.
[0331] Synthesis of three-segment PA2-PA1-PA2 fibers
[0332] The synthesis was performed similarly to the synthesis of three-segment PA2 fibers; however, the system was seeded with PAI seed segments (previously assembled at 78 °C as per the synthesis of three-segment PA fibers) at 65 °C instead of 34 °C.
[0333] mRNA binding to PA2-PA1-PA2 fibers
[0334] mRNA-Cy3 (at 300 nM) was added to the undiluted three-segment PA2-PA1-PA2 fibers (at 925 pM) at an N / P ratio of 1. Total PA concentration following addition of mRNA was 535 pM.
[0335] Synthesis of three-segment fibers with PA4Attorney Docket NWEST-45005.601
[0336] The synthesis of three-segment PA4 fibers was performed similarly to the synthesis of three- segment PAI fibers; however, the system was seeded with PA4 seed segments (previously assembled at 82 °C) at 65 °C. For the attempted synthesis of PA4-PA1-PA4 three-segment fibers, the PA4 melt was seeded with PAI seed segments instead.
[0337] Negative-Stain Transmission Electron Microscopy (TEM)
[0338] Negative-stain transmission electron micrographs were obtained using a Gatan OneView camera on a JEOL 1400 Flash TEM with a LaB6 filament at 120 kV accelerating voltage.
[0339] Copper grids with a carbon support film (CF300-Cu, Electron Microscopy Science) were glow discharged for 15 seconds at 15mA, 0.39 mBar using a PELCO easiGlow™ system. 5 pL of 500 pM (unless otherwise stated) sample was deposited onto a grid, left for 30 seconds, then wicked using filter paper. The grid was immediately placed face down on a droplet of 200 nm filtered 1 wt% uranyl acetate solution in water. After 30 seconds, the grid was lifted off the droplet and the remaining liquid was again wicked away using filter paper. The grid was left to air dry for several minutes.
[0340] Cryogenic Transmission Electron Microscopy ( cryo-TEM)
[0341] Cryo-TEM videos were obtained using a Falcon4 direct electron detector on a ThermoFisher Glacios TEM with a Schottky X-FEG electron gun at 200 kV accelerating voltage. Data collection was semi-automated using a cryogenic autoloader and ThermoFisher EPU software. The following settings were used for EPU data acquisition: 40 e / A2dose, 0.97 A pixel size, and defocus values between -3.0 pm and -0.6 pm. C-flat™ holey carbon copper grids (CF313, Electron Microscopy Science) were glow discharged for 30 seconds at 15 mA, 0.39 mBar using a PELCO easiGlow™ system. 4 pL of 50 - 150 pM sample was deposited onto a grid and vitrified in liquid ethane using a Vitrobot Mark IV (ThermoFisher) with the following settings: 4°C, 100% humidity, 3 seconds blot time, blot force 1, 1 second wait time, and 2 seconds drain time. Grids were transferred to liquid nitrogen, clipped with C-rings, and loaded into a 12 grid cassette compatible with the autoloader.
[0342] CryoSPARC was used to process and analyze cryo-EM data. After importing the movies, patch motion correction and patch contrast transfer function (CTF) estimation was performed. The filament tracer module was used to extract particles from the micrographs with the following custom settings: 200 A filament diameter, 0.3 separation distance between segments (diameters),Attorney Docket NWEST-45005.601
[0343] 100 A minimum filament diameter, and 300 A maximum filament diameter. 2D classification was performed on the extracted particles, and selected 2D classes were used as templates for a second round of particle extraction using filament tracer. 2D classification was performed on the second round of extracted particles with a maximum resolution of 3 A and a maximum alignment resolution of 6 A. 2D classes were selected based on resolution and effective classes assigned (ECA), and an average power spectrum was produced for each selected class. The power spectra were cropped for clarity.
[0344] Analysis of the nanofiber twist was done on denoised micrographs. Pixel intensity profiles were taken along the length of 100+ nanofibers per sample, and a fast Fourier transform (FFT) was calculated for each profile.
[0345] Variable Temperature Polarized Light Microscopy (VT-PLM)
[0346] Sample prepared at ImM was loaded into a 1.0 X 1.0 mm borosilicate glass capillary (Vitrocom Inc.). Both sides of the capillary were then sealed with UV Clear Fly Finish (Loon Outdoors), which was cured using a 365 nm lamp. The filled capillary was mounted on a Linkam LTS420E-P stage at 45° between cross polarizers on a Nikon LV100POL microscope. The stage was heated at 1 °C / min and cooled without a set rate by turning off the stage and allowing the heat to dissipate - a micrograph was taken every 2 minutes. The average pixel intensity for a region of interest (RO I) within the borders of the capillary was calculated for each frame using Image!. Percent average pixel intensity, (1 - (Io-I) / (Io-Imin))*100, was plotted against temperature to generate a heating / cooling curve.
[0347] Solution small-angle X-ray scattering (SAXS) and wide-angle X-ray scattering (WAXS)
[0348] X-ray scattering experiments were performed at Beamline 16-ID (LiX), National Synchrotron Light Source II, Brookhaven National Laboratory. Measurements were performed using home-built sample cells comprising of two pieces of 100- pm thick G-Leaf glass (Nippon Electric Glass America; Schaumburg, Illinois) as window materials attached to both sides of a 2 mm thick acrylic strip with 9474LE double-stick adhesive sheets (3 M; St. Paul, MN, USA). Cast acrylic plates and double-stick sheets were laser-cut to form strips with 14 sample cells (cell dimensions: 6mm X 3mm), each with an opening at the top.1Strips with empty cells were placed on a rack inside the beamline hutch, and a 6-axis robot mounted them one at a time on a translational stage in the beam path. Eight strips could be placed on the rack and measuredAttorney Docket NWEST-45005.601
[0349] without opening the hutch. An X-ray energy of 15 keV was selected using a Si( 111 ) monochromator, and the scattering patterns for the empty cells were recorded using a set of Pilatus3 pixel array detectors.2The cells were then filled with either buffer or sample through the opening at the top, placed back on the rack inside the hutch, and measured. The two-dimensional scattering patterns were azimuthally integrated to generate a scattering vector magnitude q vs. intensity plot. Here, q is defined as q = 47tsin(0) / , where 9 denotes half of the total scattering angle and X the X-ray wavelength, 0.8266 A. 2D to ID data reduction and subsequent subtraction was performed using tools developed by LiX.2ID profiles from empty cell measurements were subtracted from buffer / sample ID profiles before scaled buffer subtraction to accurately remove scattering contributions from the glass windows.
[0350] Fluorescence confocal laser scanning microscopy ( CLSM)
[0351] CLSM characterization was performed on a Nikon A1R+ instrument equipped with a Nikon CFI Plan Apochromat VC 60X objective (NA = 0.95). Cy3 was imaged in the red channel (excitation: 562 nm emission: 570-620 nm), while Cy5 was imaged in the far-red channel (excitation: 641 nm, emission: 663-738 nm). Non-segmented fibers were imaged in resonant mode, while segmented fibers were imaged in galvano mode. For samples prepared for CLSM, dye labelled PA was mixed with the unlabeled PA (with the same amino acid sequence - unless otherwise stated) in HFIP. Once assembled, samples with positive charge were diluted in IxPB pH 7.4 with 150 mM NaCl. while samples with negative charge were diluted in 10 mM NaOH with 1 M NaCl. For imaging single fibers, samples were diluted to 0.25 pM, while for more general imaging, fibers were diluted to between 10 and 50 pM. Double sided adhesive 1 mM thick with oval shaped cutouts (each ~ 5 mM long) was attached to a glass slide. 1 pL of sample was pipetted into the cutouts and the cover slip was very gently placed on top to sandwich the sample. The setup was then slowly turned over such that the cover slip was facing down and left on a flat surface to adhere for ~ 2 minutes prior to imaging.
[0352] Atomic force microscopy
[0353] AFM experiments were done in air at room temperature using a Veeco Dimension icon scanning probe microscope (Veeco) and a Nanoscope V Controller (Bruker). SNL-10-A probes (nominal tip radius of 2 nm and spring constant of 0.35 N m-1; Bruker) were used with ScanAsyst imaging mode. Samples were diluted to 50 pM in ultrapure water and 5 pL wasAttorney Docket NWEST-45005.601
[0354] deposited on freshly cleaved mica. 50 pL of water was then added and the excess wicked away before a strong stream of compressed air was immediately applied to dry the surface. Samples were further dried under vacuum for at least 30 minutes prior to imaging.
[0355] Measurement of fiber lengths and statistical analysis
[0356] Fiber lengths were measured by hand using Fiji software37. Every fiber that was completely within the field of view of an image was measured unless fibers were tangled in a way that made distinguishing their paths impossible. At least 100 individual fibers were measured per sample. The measurements were then randomized and 100 values plotted.
[0357] The number average length (LN), weight average length Lw , and the dispersity (D) were calculated as described below:
[0358] (2) Xf=1NiLi
[0359] Lw
[0360] (3)
[0361]
[0362] LN
[0363] Where Li is the length of fiber i and Ni is the number of fibers i.
[0364] Variable temperature fluorescence
[0365] Nile red segregates into the hydrophobic environment of the PA fiber cores, where its fluorescence is greatly enhanced due to solvatochromism38. Upon nanofiber melting, nile red is exposed to the aqueous solution and fluorescence is quenched. Samples were initially prepared as per the general self-assembly of peptide amphiphile nanofibers method without heating. 1 pL of 100 pM nile red in ethanol was added to 60 pL of sample and briefly vortexed. Variable temperature fluorescence was performed using a Bio-Rad CFX96 Real Time PCR Detection System with a Bio-Rad C1000 Touch Thermal Cycler. Samples were divided into 3 x 20 pL andAttorney Docket NWEST-45005.601
[0366] heated from 25 °C to 99 °C at 1 °C / min, held at 99°C for 1 hour, then cooled from 99 °C to 1 °C at 1 °C / min unless otherwise stated. Fluorescence was measured every 30 seconds in the ROX channel (excitation: 560-590 nm, detection: 610-650 nm) during heating and cooling. The fluorescence of the triplicate samples was averaged at each time point.
[0367] Melting analysis of pre-assembled self-seeded length-defined fibers
[0368] Samples of length-defined fibers were generated as per the self-seeding protocol. The melting curves of these samples were analysed as per the general melting analysis method, except the samples were only gently pipette mixed following the addition of nile red, rather than vortexed. Also, the fluorescence was only measured during heating.
[0369] Circular dichroism
[0370] Measurements were taken using a J- 1700 Circular Dichroism Spectrophotometer from Jasco. Samples were diluted to 50 pM in IxPB pH 7.4 with 150 mM NaCl and 150 pL was added to a 1 mm pathlength quartz cuvette. Three accumulations were recorded for each sample from 300 to 200 nm with a data pitch of 0.5 nm, a digital integration time of 4 s, a bandwith of 2 nm, and a scanning speed of 50 nm / min. The molar ellipticity was then calculated on a per amino acid basis.
[0371] Sholl Analysis
[0372] Shell analysis was performed using the Simple Neurite Tracer (SNT) plugin in ImageJ to semi-automatically reconstruct the TUJ 1 channel. Branching complexity was analyzed using the Sholl plugin in Fiji.
[0373] It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the disclosure, which is defined solely by the appended claims and their equivalents.
[0374] Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses,Attorney Docket NWEST-45005.601
[0375] compositions, formulations, or methods of use of the disclosure, may be made without departing from the spirit and scope thereof.
[0376] Any patents and publications referenced herein are herein incorporated by reference in their entireties.
Claims
Attorney Docket NWEST-45005.601CLAIMS1. A peptide amphiphile comprising a hydrophobic tail, a -sheet forming peptide segment, a charged peptide segment comprising one or more repeating XGG units, and a PEG domain, wherein X is a positively charged amino acid or a negatively charged amino acid.
2. The peptide amphiphile of claim 1, wherein the hydrophobic tail comprises an 8-24 carbon alkyl chain (Cs-24).
3. The peptide amphiphile of claim 1 or claim 2, wherein the -sheet forming peptide segment comprises 2 to 6 amino acids and has a total propensity for forming 0-sheet conformations of at least 4.
4. The peptide amphiphile of claim 3, wherein the 0-sheet forming peptide segment comprises V2A2.
5. The peptide amphiphile of any one of claims 1-4, wherein the PEG domain comprises a PEG containing 10 to 30 repeating ethylene glycol subunits.
6. The peptide amphiphile of any one of claims 1-5, wherein the charged peptide segment comprises 2 to 10 repeating XGG units.
7. The peptide amphiphile of claim 6, wherein the charged peptide segment comprises 2 to 4 repeating XGG units.
8. The peptide amphiphile of any one of claims 1-7, wherein X is arginine (R).
9. The peptide amphiphile of claim 8, wherein the charged peptide segment comprises (RGG)3.Attorney Docket NWEST-45005.60110. The peptide amphiphile of any one of claims 1 -7, wherein X is glutamic acid (E).
11. The peptide amphiphile of claim 10, wherein the charged peptide segment comprises (EGG) .
12. The peptide amphiphile of any one of claims 1-11, wherein the P-sheet forming peptide segment is conjugated to the charged peptide segment by a linker.
13. The peptide amphiphile of claim 12, wherein the linker comprises a single glycine (G) residue.
14. A nanofiber comprising the peptide amphiphile of any one of claims 1-13.
15. A segmented nanofiber comprising a positively charged peptide amphiphile segment flanked on one end by a first negatively charged peptide amphiphile segment and flanked on the other end by a second negatively charged peptide amphiphile segment, wherein:a) the positively charged peptide amphiphile segment comprises one or more positively charged peptide amphiphiles, each positively charged peptide amphiphile comprising a hydrophobic tail, a P-sheet forming peptide segment, a positively charged peptide segment comprising one or more repeating XGG units, wherein X is a positively charged amino acid, and a PEG domain,b) the first negatively charged peptide amphiphile segment and the second negatively charged peptide amphiphile segment each comprise one or more negatively charged peptide amphiphiles, each negatively charged peptide amphiphile comprising a hydrophobic tail, a P-sheet forming peptide segment, a negatively charged peptide segment comprising one or more repeating XGG units, wherein X is a negatively charged amino acid, and a PEG domain.
16. The segmented nanofiber of claim 15, wherein the hydrophobic tail of the one or more positively charged peptide amphiphiles and the one or more negatively charged peptideAttorney Docket NWEST-45005.601amphiphiles comprises an 8-24 carbon alkyl chain (Cs-24).
17. The segmented nanofiber of claim 15 or claim 16, wherein the P-sheet forming peptide segment of the one or more positively charged peptide amphiphiles and the one or more negatively charged peptide amphiphiles comprises 2 to 6 amino acids and has a total propensity for forming P-sheets of at least 4.
18. The segmented nanofiber of claim 17, wherein the P-sheet forming peptide segment of the one or more positively charged peptide amphiphiles and of the one or more negatively charged peptide amphiphiles comprises V2A2.
19. The segmented nanofiber of any one of claims 16 to 18, wherein the PEG domain of the one or more positively charged peptide amphiphiles and the one or more negatively charged peptide amphiphiles comprises a PEG containing 10-30 repeating ethylene glycol subunits.
20. The segmented nanofiber of any one of claims 16 to 20, wherein the positively charged peptide segment and the negatively charged peptide segment comprise 2 to 10 repeating XGG units.
21. The segmented nanofiber of claim 21, wherein the positively charged peptide segment and the negatively charged peptide segment comprise 2 to 4 repeating XGG units.
22. The segmented nanofiber of any one of claims 16 to 22, wherein the positively charged amino acid is arginine (R).
23. The segmented nanofiber of claim 23, wherein the positively charged peptide segment comprises (RGG)3.
24. The segmented nanofiber of any one of claims 16 to 22, wherein the negatively charged amino acid is glutamic acid (E).Attorney Docket NWEST-45005.60125. The segmented nanofiber of claim 24, wherein the negatively charged peptide segment comprises (EGG)3.
26. The segmented nanofiber of any one of claims 15 to 25, wherein the positively charged peptide amphiphile segment comprises less than 30%, less than 20%, or less than 15% of the entire nanofiber by length.
27. The segmented nanofiber of any one of claims 15 to 26, wherein the two negatively charged peptide amphiphile segments have asymmetric lengths.
28. The segmented nanofiber of claim 27, wherein the length of the first negatively charged peptide amphiphile segment is at least 50% greater than the length of the second negatively charged peptide amphiphile segment.
29. The segmented nanofiber of claim 28, wherein the length of the first negatively charged peptide amphiphile segment is at least double the length of the second negatively charged peptide amphiphile segment.
30. The segmented nanofiber of any one of claims 15-29, having a total length of at least 5 pm.
31. The segmented nanofiber of claim 30, having a total length of at least 10 pm.
32. The segmented nanofiber of claim 30, having a total length of at least 20 pm.
33. The segmented nanofiber of claim 30, having a total length of 5 to 35 pm.
34. The segmented nanofiber of any one of claims 15-33, having a molecular weight of 1.0 x 108g / mol to 2.25 x 109g / mol.Attorney Docket NWEST-45005.60135. A method comprising contacting a cell with the segmented nanofiber of any one of claims 15 to 34.
36. The method of claim 35, wherein the cell is a neuron.
37. A cell cultured on the segmented nanofiber of any one of claims 15 to 34.
38. The cell of claim 37, wherein the cell is a neuron.
39. A system comprising a cell and the segmented nanofiber of any one of claims 15-34, wherein electrostatic interactions between the positively charged peptide amphiphile segment and the cell membrane anchor the nanofiber to the cell membrane, and wherein the negatively charged peptide amphiphile segments bind to extracellular proteins in proximity to the cell.
40. The system of claim 39, wherein at least 90% of the entire length of the segmented nanofiber is anchored to the cell membrane.
41. The system of claim 39 or claim 40, wherein the cell is a neuron.
